2016N302761_00 CONFIDENTIA L
ViiV Healthcare and the GlaxoSmithKline group of companies 205893
1TITLE PA GE
Protocol Title: A 2-Part, Phase I, Single Dose, Crossover Relative Bioavailability  Study  
of Both TIVI CAY 10mg Conventional Tablets and 5 mg Dispersible Tablets Compared 
to Conventional TI VICAY Tablets in Healthy  Adult Subjects
Protocol Number : 205893
Short Title : Relative Bioavailability  Study  of Pediatric Formulation sin Healthy  Adult 
Subjects
Compound Number: [COMPANY_004]1349572
Sponsor Name [CONTACT_29560]: 
This study  is sponsored by  [CONTACT_103673].  GlaxoSmithKline is implementing and 
managing all aspects of this study .
ViiV Healthcare
[ADDRESS_938020]
P.O. [ZIP_CODE]
Research Triangle Park, NC
[ZIP_CODE]- 3398, [LOCATION_003]
SAE email:  and 
Back -upMedical Monitor
 M.D.
[ADDRESS_938021]
Collegeville, PA [ZIP_CODE]
Regulatory A gency Identifying Number(s): 75,382
Approval Date:   23-FEB-2017
Copy right 2017 the ViiV Healthcare and the GlaxoSmithKline group of companies.  All 
rights reserved.  Unauthorised cop ying or use of this information is prohibited.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
PP
D
[COMPANY_003]
2016N302761_00 CONFIDENTIA L
205893
3TABLE OF CONTENTS
PAGE
1.SYNOPSIS ................................................................
............................................... 6
2.SCHEDULE OF ACTIVITIES (SOA) ....................................................................... 11
2.1. Screening Assessments ............................................................................. 11
2.2. Time and Events Table ............................................................................... 12
3.INTRODUCTION .................................................................................................... 13
3.1. Study Rationale .......................................................................................... 13
3.2. Background ................................................................................................ 13
3.3. Benefit/Risk Assessment ............................................................................ 13
3.3.1. Risk Assessment ......................................................................... 14
3.3.2. Benefit Assessment ..................................................................... 15
3.3.3. Overall B enefit:Risk Conclusion ................................................... 15
4.OBJECTIVES AND ENDPO INTS ........................................................................... 16
5.STUDY DESIGN .................................................................................................... 17
5.1. Overall Design ............................................................................................ 17
5.2. Treatment Groups and Duration ................................................................ .17
5.3. Number of Participants ............................................................................... 18
5.4. Participant and Study Completion ............................................................... 19
5.5. Scientific Rationale for Study Design .......................................................... 19
5.6. Dose Justifi cation ........................................................................................ 19
6.STUDY POPULATION ........................................................................................... 20
6.1. Inclusion Criteria ......................................................................................... 20
6.2. Exclusion Criteria ........................................................................................ 21
6.3. Lifestyle Restrictions ................................................................................... 23
6.3.1. Meals and Dietary Restrictions .................................................... 23
6.3.2. Fasting Conditions ....................................................................... 23
6.3.3. Fed Conditions ............................................................................ 23
6.3.4. Caffeine, Alcohol, and Tobacco ................................................... 23
6.3.5. Activity ......................................................................................... 23
6.4. Screen Failures ........................................................................................... 23
7.TREATMENTS ....................................................................................................... 24
7.1. Treatments Administered ............................................................................ 24
7.1.1. Dosing Dispersible Tablet s in Treatment C .................................. 25
7.2. Blinding ....................................................................................................... 25
7.3. Preparation/Handling/Storage/Accountability .............................................. [ADDRESS_938022] to Follow Up ........................................................................................ 29
9.STUDY A SSESSMENTS AND PROCE DURES ..................................................... 30
9.1. Adverse Events ........................................................................................... 31
9.1.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 31
9.1.2. Method of Detecting AEs and SAEs ............................................. 31
9.1.3. Follow -up of AEs and SAEs ......................................................... 32
9.1.4. Regulatory Reporting Requirements for SAEs ............................. 32
9.1.5. Pregnancy ................................................................................... 32
9.2. Treatment of Overdo se............................................................................... 32
9.3. Safety Assessments ................................................................................... 33
9.3.1. Physical Examinations ................................................................ .33
9.3.2. Vital Signs .................................................................................... 33
9.3.3. Electrocardiograms ...................................................................... 33
9.3.4. Clinical Safety Laboratory Assessments ...................................... 33
9.4. Pharmacokinetics ....................................................................................... 35
9.4.1. Blood Sample Collection .............................................................. 35
9.4.2. Sample Analysis .......................................................................... 35
9.5. Formulation Palatability Assessment .......................................................... 35
10.STATISTICAL CONSIDER ATIONS ........................................................................ 35
10.1. Hypotheses ................................................................................................ .35
10.2. Sample Size Considerations ....................................................................... 36
10.2.1. Sample Size Assumptions ........................................................... 36
10.2.2. Sample Size Sensitivity ................................................................ 36
10.2.3. Sample Size Re- estimation .......................................................... 36
10.2.4. Analysis Populations .................................................................... 36
10.2.5. Interim Analyses .......................................................................... 37
10.3. Key Elements of Analysis Plan ................................................................... 37
10.3.1. Primary Analyses ......................................................................... 37
[IP_ADDRESS]. Pharmacokinetic Analyses .......................................... 37
[IP_ADDRESS]. Safety Analyses .......................................................... 38
10.3.2. Palatability Questionnaire ............................................................ 38
11.REFERENCES ....................................................................................................... 39
12.APPENDICES ........................................................................................................ 40
12.1. Appendix 1: Abbreviat ions and Trademarks ................................................ 40
12.2. Appendix 2: Liver Safety Required Actions and Follow up 
Assessments .............................................................................................. 42
12.3. Appendix 3: Study Governance Considerations .......................................... 44
12.4. Appendi x 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 48
12.5. Appendix 5: Modified List of Highly Effective Methods for Avoiding 
Pregnancy in FRP and Collection of Pregnancy Infor mation ....................... [ADDRESS_938023] of Highly Effective Methods for Avoiding 
Pregnancy in Females of Reproductive Potential (FRP) .............. 53
12.5.2. Collection of Pregnancy Information ............................................ 53
12.5.3. Appendix 5 References ................................................................ 54
12.6. Appendix 6 -Division of AIDS Table For Grading The Severity Of 
Adult And Paediatric Averse Events Version 2.0, November 2014 .............. 55
2016N302761_00 CONFIDENTIA L
205893
512.7. Appendix 7: Toxicity Management ............................................................. [ADDRESS_938024] AND ALT ELEVATION ......................................................... 75
12.7.4. RASH .......................................................................................... 75
12.7.5. ALLERGIC REACTION ................................................................ 77
12.7.6. CREATINE PHOSPHATE (CPK) ELEVATION ............................ 78
12.8. Appendix 8: Palatability Questionnaire ........................................................ 79
2016N302761_00 CONFIDENTIA L
205893
61. SYNOPSIS
Protocol T itle: A 2-Part, Phase I, Single Dose, Crossover Relative Bioavailability  Study  
of Both TIVI CAY 10mg Conventional Tablets and 5 mg Dispersible Tablets Compared 
to Conventional TI VICAY Tablets in Fasted Healthy  Adult Subjects
Short Title: Pediatric Relativ e Bioavailabilit y Study in Healthy Adult Subjects
Rationale
TIVICAY (dolutegravir [ DTG ], [COMPANY_004]1349572) 50mg conventional tablet is for the 
treatment of Human Immunodeficiency  Virus (HIV)infection in adults and adolescents. 
Recently  two lower pediatric strength conventional tablets (10mg and 25mg) were 
approved in the [LOCATION_002] ( US)and received a positive opi[INVESTIGATOR_691700] ( EU).  A dispersible tablet formulation (5milligram [ mg]tablet for oral 
suspension) of TIVICAY has been developed for administration in y ounger pediatric
populations. This study  will be conducted in 2 separate parts with separate groups of 
fasted healthy  adult subjects to investigate both 10 mg conventional tablets (Part 1) and 5 
mg dispersible tablets (Part 2).  Part 1 of the stud y will compare the relative 
bioavailability  (BA)of five 10 mg conventional tablets (test) to that of one 50 -mg 
conventional tablet (reference) in one group of subjects.  Part 2, will be a 
pharmacokinetic (PK) evaluati on of 5 mg DTG dispersible tablet scompared to the 
conventional 25 mg tablet of TIVICAY taken with water. The randomized cross -over 
treatments in Part 2 are:  1) 5 mg dispersible DTG tablet (5 tablets) administered as a 
dispersion and immediately  taken (test 1) , 2) 5 mg dispersible DTG tablet (5 tablets) 
administered as direct to mouth (test 2) ,and 3) the conventional [ADDRESS_938025] to mouth (reference) .
Objectives and Endpoints
Part 1
Objective Endpoint
Primary
To evaluate the rel ative BA of DTG convent ional 10 mg 
tablets (5 tablets) administered direct to mouth a s 
compared to a conventional 50 mg tablet ( reference ) 
administered direct to mouth.Plasma DTG AUC (0-∞), AUC (0-t), and C max
Secondary
To compare the single dose PK of DTG conventional 
10mg tablets (5 tablets) administered direct to mouth 
as compared to a conventional 50 mg tablet (reference) 
administered direct to mouth.
To evaluate the safety and tole rability of DTG 
conventional 10 mg (5 tablets) administered direct to 
mouth as compared to the administration of a 
conventional 50 mg tablet (reference) administered 
direct to mouth.Plasma DTG tlag, tmax, t, t ½, z, %AUC ex, AUC (0-24), CL/F 
and Vz/F, Ct, a nd C 24
Safety and tolerability parameters as assessed by 
[CONTACT_691718]
2016N302761_00 CONFIDENTIA L
205893
7Part 2
Primary
To evaluate the r elative BA of DTG dispersible 5 mg 
tablets (5 t ablets) administered as “disperse and 
immediately take” and of DTG dispersible 5 mg tablets (5 
tablets) administered direct to mouth a s compared to a 
conventional 25 mg tablet (reference) administered direct 
to mouth. Plasma DTG AUC (0-∞), AUC (0-t), and C max
Secondary
To compare the single dose PK of DTG dispersible 5 
mg tablets (5 tablets) administered as “disperse and 
immediately take” and of DTG dispersible 5 -mg tablets 
(5 tablets) administered direct to mouth a s compared to 
a conventional 25 mg tablet (reference) administered 
direct to mouth.
To evaluate the safety and tolerability of DTG 
dispersible 5 -mg tablets (5 tablets) administered as 
“disperse and immediately take” and of DTG dispersible 
5-mg tablets (5 tablets) administered direct to mouth a s 
compared to a conventional 25 mg tablet (reference) 
administered direct to mouth.Plasma DTG t lag, tmax, t, t ½, z, %AUC ex, AUC (0-24), CL/F 
and Vz/F, Ct, and C 24
Safety and tolerability parameters as assessed by 
[CONTACT_691719] s with 
adverse events and toxicity grading of clinical 
laboratory tests
Exploratory
To evaluate the palatability of the dispersible tablets.   Palatability Questionnaire
Study Design
This study  will be conducted as a 2-part, open -label ,randomized, cross- over design with 
one group of subjects in Part 1 of the study  randomized to receive each of 2 study  
treatments (A and B) over 2 dosing periods, and another group of subjects in Part 2 of the 
study  randomized to receive each of 3 study  treatments (C, D, a nd E) over [ADDRESS_938026] 7 ( -4 hours) day s 
between doses of study  medication .
Study Design – Part 1 of the StudyScreening 
(≤30 days)Treatment Period 1
Treatment A: 
or
Treatment B:  
Washout of 7 daysTreatment Period 2
Treatment A: 
or
Treatment B: Follow-up ([ADDRESS_938027] 
dose)
2016N302761_00 CONFIDENTIA L
205893
8Study Design – Part 2 of the Study
Treatment Period 1
Treatment C: 
or
Treatment D: 
or
Treatment E: Treatment Period 2
Treatment C: 
or
Treatment D: 
or
Treatment E: Treatment Period 3 
Treatment C: 
or
Treatment D: 
or
Treatment E: Screening 
(≤30 days)
Washout of 7 daysWashout of 7 daysFollow -up ([ADDRESS_938028] 
dose)
Treatment Groups and Duration
The study  treatments to be administered in Part 1 of the study  are:
Treatment A:  Conventional 10 mg DTG tablet ([ADDRESS_938029] ) administered direct to 
mouth .
Treatment B :  Conventional 50 mg DTG tablet ( reference ) administered direct to 
mouth
Part 1 –Two -Period Crossover
Sequence (Total N=1 4) Period 1 Period 2
1 (n=7) A B
2 (n=7) B A
The study  treatments to be administered in Part 2 of the study  are:
Treatment C:  5 mg dispersible DTG tablet (5 tablets) administered as a dispersion 
and immediately  taken (test 1).
Treatment D:  5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth
(test 2).
Treatment E:  Conventional [ADDRESS_938030] to mouth
(reference).
Part 2 –Three -Period Crossover
Sequence (Total N= 24) Period 1 Period 2 Period 3
1 (n=4) C D E
2 (n=4) D E C
3 (n=4) E C D
4 (n=4) C E D
5 (n=4) D C E
6 (n=4) E D C
The total duration of participation for a subject parti cipating in Part [ADDRESS_938031] dose of study  drug.  At Follow -up, m ale subjects with no ongoing adverse 
events ( AEs)or Vital Sign/L aboratory  measures of clinical concern may  be followed 
virtually  by [CONTACT_503371].
To ensure adequate washout, ther e will be at least 7 day s between dosing periods, with an 
allowance window of 4 hrs (i.e., 7 day s minus 4 hrs) to allow for flexibility  in scheduling 
subjects to dose at the clinic.
PK samples will be collected for 72 hrs after each dose of study  drug.
Num ber of Participants
Approximately  14 subjects (to achieve 12 completed subjects) will participate in Part 1 of 
the study , and approximately  24 subjects (to achieve 18 evaluable subjects) will 
participate in Part [ADDRESS_938032] will participate in onl y one part of the study.  
If participant s prematurely  discontinue the study for reasons other than AE , additional 
replacement participant smay be assigned to the same treatment group sequence at the
discretion of the Sponsor in consultation with the investigator .
Analysis
Pharmacokinetic anal yses will be the responsibility  of the Clinical Pharmacology  
Modeling & Simulation department within [COMPANY_004] or their designee.  Plasma DTG 
concentration -time data will be anal yzed by [CONTACT_105] -compartmental methods with P hoenix 
WinNonlin.  Calculations will be based on the actual sampling times recorded during the 
study .  From the plasma concentration- time data, the following PKparameters will be 
determined, as data permit:  AUC (0-), area under the plasma concentration -time curve 
from time of dose to last measurable concentration ( AUC (0-t)), area under the plasma 
concentration -time curve from time of dose to 24 hr (AUC 0-24), maximum observed 
concentration (Cmax), plasma DTG lag time for absorption (tlag), time of occurren ce of 
Cmax (tmax), t, t erminal elimination phase half -life(t1/2), terminal rate constant (z), 
%AUCex, a pparent oral clearance (CL/F)and apparent volume of distribution during
terminal phase (Vz/F ), Ct, and c oncentration at 24 hours after dose administra tion (C24).
Pharmacokinetic data will be listed and may  be presented in graphical form and will be 
summarized descriptively.  All PK data will be stored in t he Archives, GlaxoSmithKline 
Research and Development (R& D) or their designee . 
The PK parameters ( except for t maxand t lag) for DTG will be log e-transformed and 
separately  anal yzed using a mixed effects model with fixed effect terms for period and 
treatment for each treatment comparison .  Subject will be treated as a random effect in 
the model.  Point estimates and their associated 90% CI s will be constructed for the 
differences in PK parameter values between test and reference treatments.  The point 
estimates and their associated 90% CIs will then be back -transformed to provide point 
2016N302761_00 CONFIDENTIA L
205893
10estimates and 90% CIs for the ratios of PK parameters between test and reference 
treatments.
Safety  data will be presented in tabular format and summarized descriptively  according to 
[COMPANY_004]’s Integrated Data Standards Library  (IDSL) standards. No formal statistical analy sis 
ofthe safet y data will be conducted.
Palatability  questionnaire variables will be summarized descriptively .
2016N302761_00 CONFIDENTIA L
205893
112. SCHEDULE OF ACTIVITI ES (SOA )
2.1. Screening A ssessments
Screening procedures (Table 1) may be done over more than one visit but must all be 
completed within [ADDRESS_938033] dose of study  drug .  The following 
demographic parameters will be captured: year of birth, sex , race and ethnicity .  
Medical/medication/family  history  will be assessed as related to the inclusion/exc lusion 
criteri a.
Table 1 Screening A ssessments
Event Notes
Informed Consent
Demographics
Medical history (includes substance usage )
Inclusion/Exclusion
HIV, Hep B and Hep C screen
Drug/alcohol screen
Brief Physical Exa m
Height, Weight & BMI 
Vital Signs
12-lead ECG (single)
FSH and estradiol (women)
Pregnancy test (serum) For Women of Child Bearing Potential (WCBP) only
Clinical Laboratory Tests (Chemistry, hematology, & 
urinalysis)For Clinical laboratory Te sts, see Section 9.3.4
2016N302761_00 CONFIDENTIA L
205893
122.2. Time and Events Table
Table 2 Treatment Period Time and Events
AssessmentsAll Study Periods (Parts 1 and 2)
Follow-upNotes
Day - 1 of Periods 2 -3may be the s ame day as Day 6 
of prior periods
At Follow -up –Male subjects with no ongoing AEs or 
Vital Sign/Laboratory measures of clinical concern may 
be followed virtually by [CONTACT_503371].Day -1Day [ADDRESS_938034] dose.
12-lead ECG (single) X
Vital signs X X X X XSingle vital sign measurements performed at all time points.
Brief Physical Exam X Drug/Alcohol/Cotinine /pregnancy will be performed per 
the standard practice of the site.
Clinical laboratory tests –seeTable 5 ,Section 9.3.4 .
*Clinical laboratory tests at follow -up are only necessary if 
subject had a previous abnormal lab valueUrine Drug/Alcohol/Cotinine X
Pregnancy test (urine; WCBP) X X
Clinical laboratory tests X X X*
Dosi ng X See Section 7.1
Palatability AssessmentStart within 10 
min after doseComplete fo r each dispersion treatment C(see Section 
12.8, Appendix 8)
PK Sampling XCollect at: 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 
16, 24, [ADDRESS_938035] -dose .Pre-dose (within 15 minutes prior to dosing), Section 9.[ADDRESS_938036] for the study center See also Section 6.3.2 and Section 6.3.3
Adverse Events / SAE X========== ============X==================== == X
Concomitant medications X========= =============X======== ==============  X
2016N302761_00 CONFIDENTIA L
205893
133. INTRODUCTION
3.1. Stud y Rationale
TIVICAY (dolutegravir [ DTG ], [COMPANY_004]1349572) 50mg conventional tablet is for the 
treatment of Human Immunodeficiency  Virus (HIV)infection in adults and adolescents. 
Recently  two lower pe diatric strength conventional tablets (10mg and 25mg) were 
approved in the [LOCATION_002] ( US)and received a positive opi[INVESTIGATOR_691700] ( EU).  A dispersible tablet formulation (5milligrams [ mg]tablet for oral 
suspension) of TIVICAY has been d eveloped for administration in y ounger pediatric
populations. This study  will be conducted in 2 separate parts with separate groups of 
fasted healthy  adult subjects to investigate both 10 mg conventional tablets (Part 1) and 5 
mg dispersible tablets (Part 2).  Part 1 of the stud y will compare the relative 
bioavailability  (BA)of five 10 mg conventional tablets (test) to that of one 50 -mg 
conventional tablet (reference) in one group of subjects.  Part 2, will be a 
pharmacokinetic (PK) evaluati on of 5 mg DTG dispersible tablet scompared to the 
conventional 25 mg tablet of TIVICAY taken with water. The randomized cross -over 
treatments in Part 2 are:  1) 5 mg dispersible DTG tablet (5 tablets) administered as a 
dispersion and immediately  taken (test 1), 2) 5 m g dispersible DTG tablet (5 tablets) 
administered as direct to mouth (test 2), and 3) the conventional [ADDRESS_938037] to mouth (reference).
3.2. Background
TIVICAY (D TG)as a single drug entity  was first approved in the US in August [ADDRESS_938038] PK variability , a predictable 
exposure -response relationship, and a 14- hour plasma half -life that supports once -daily 
dosing without the need for the PK boosters. In addition, DTG lacks man y of the 
associated drug interactions, specifically with oral contraceptives, statins, antidepressants, 
anxioly tics, anticoagulants, and other medications commonly  taken b yHIV-positive 
patients.  
Alternate for mulations and dosing strategies (e.g., pediatric granules and dispersible 
tablets) are being developed for pediatric patients less than [ADDRESS_938039] 
difficulty  swallowing conventional tablet formulations.   Since the solubility of DTG is 
reduced when co -administered with divalent cation -containing products,
the relative BA 
of DTG in dispersible tablets dispersed in either High Mineral Content (Contrex brand 
mineral water ;contains high levels of calcium and magnesium) or Low Mineral Content 
Water (10% Contrex/90% Purified water) has been evaluated previousl y.  Mineral 
content had no effect on the relative bioavailability of dispersed tablets ( Clinical 
Investigator's Brochure [GlaxoSmithKline Document Number RM2007/[ZIP_CODE]/10 ]).
3.3. Benefit/Risk A ssessment
More detailed information about the known and expected benefits and risks and 
reasonabl y expected adverse events of DTG may be found in the Investigator’s Brochure .
2016N302761_00 CONFIDENTIA L
205893
143.3.1. Risk A ssessment
Poten tial Risk of Clinical 
SignificanceData/Rationale for Risk Mitigation Strategya
Refer to Investigator Brochure ( IB)for additional 
information
Hypersensitivity reaction 
(HSR) and rashHSR has been observed uncommonly with DTG.  Rash 
was commonly reported in DTG Phase IIb/III clinical 
trials; epi[INVESTIGATOR_691701]; no epi[INVESTIGATOR_473385], such as Stevens -
Johnson Syndrome (SJS), Toxic Epi[INVESTIGATOR_19342] 
(TEN) and erythema multiforme were reported.Subjects with histo ry of allergy/sensitivity to any of the s tudy drugs are excluded 
(Section 6.2)
Specific/detailed toxicity management guidance is provided for HSR and rash 
(Section 12.7).
For Grade 3/[ADDRESS_938040] permanently discontinue study drug and be 
withdrawn from the study (Section 12.7.4 )
The subject informed consent form includes information on this risk and the actions 
subjects should take in the event of an HSR or associated signs and symptoms. 
Drug induced liver injury 
(DILI) and other clinically 
significant liver chemistry 
elevationsNon-clinical data suggested a possible, albeit low, risk 
for hepatobiliary toxicity wit h DTG.  Drug- related hepatitis 
is considered an uncommon risk for antiretroviral therapy 
(ART) containing DTG regardless of dose or treatment 
population.  For subjects with hepatitis B virus (HBV) 
and/or hepatitis C virus (HCV) co -infection, 
improvements i n immunosuppression as a result of HIV 
virologic and immunologic responses to DTG -containing 
ART, along with inadequate therapy for HBV co -infected 
subjects, likely contributed to significant elevations in 
liver chemistries.Subjects meeting either of the following criteria during the screening period are excluded 
(Section 6.2).
 Current or chronic history of liver disease, or known hepatic or biliary abnormalities 
(with the exception of Gilbert's syndrome or asy mptomatic gallstones).
 Alanine Aminotransferase (ALT) or bilirubin >1.5x upper limit of normal (ULN).
 Subjects positive for HBV (hepatitis B virus surface antigen positive [+HBsAg] or
positive hepatitis B core antibody with a negative HBsAg), or HCV ( positive hepatitis 
C antibody test) within 3 months of the Day 1 study visit.
Specific/detailed liver stoppi[INVESTIGATOR_691702] (Section 12.2).
Renal functionb Mild elevations of creatinine have been observed with 
DTG which are related to a likely benign effect on 
creatinine secretion with blockade of organic cation 
transporter 2 (OCT -2).  DTG has been shown to have no 
significant effect on glomerular filtration rate or effective 
renal plasma flow.Increases in serum creatinine are not expected to have any adverse effect and will 
reverse during the wash out period after each single dosing of DTG, and; the refore, do not 
require mitigation for this protocol in this respect of DTG. 
Creatine Phosphokinase 
(CPK) elevationsAsymptomatic CPK elevations mainly in association with 
exercise have been reported with DTG therapy.Specific detailed toxicity managemen t guidance is provided for subjects who develop 
Grade 3 to 4 CPK elevations (Section 12.7.6 ).
a.Careful monitoring of events will be conducted using serious adverse event (SAE) reports and alerts for Grade 3/4 la boratory toxicities (per Division of Acquired Immune Deficiency 
Syndrome [DAIDS] toxicity grading for HIV -infected patients). Serious/severe events will be managed appropriately including, but not limited to, withdrawal of investig ational product 
(IP), and will be followed to resolution as per Sponsor’s standar d medical monitoring practices.
b.  Increases in creatinine of ~0.1 to 0.15mg/dL are expected and will reverse.
2016N302761_00 CONFIDENTIA L
[ADDRESS_938041] was 
previously  unaware of.
3.3.3. Overall Benefit:Risk Conclusion
Taking into accou nt the measures taken to minimiz e risk to subjects participating in this 
study , the potential risks identified in association with TIVICAY are low .
2016N302761_00 CONFIDENTIA L
205893
164. OBJECTIVES A ND E NDPOINTS
Part 1
Objective Endpoint
Primary
To evaluate the relative BA of DTG conventional 10 mg 
tablets (5 tablets) administered direct to mouth as 
compared to a conventional 50 mg tablet (reference) 
administered direct to mouth.Plasma DTG AUC (0-∞), AUC (0-t), and C max
Secondary
To compare the single dose PK of DTG conventional 
10 mg tablets (5 tablets) administered direct to mouth 
as compared to a conventional 50 mg tablet (reference) 
administered direct to mouth.
To evaluate the safety and tolerabil ity of DTG 
conventional 10 mg (5 tablets) administered direct to 
mouth as compared to the administration of a 
conventional 50 mg tablet (reference) administered 
direct to mouth.Plasma DTG tlag, tmax, t, t ½, z, %AUC ex, AUC (0-24), CL/F 
and Vz/F, Ct, and C 24
Safety and tolerability parameters as assessed by 
[CONTACT_691720] 2
Primary
To evaluate the relative BA of DTG dispersible 5 mg 
tablets (5 tablets) administered as “disperse and 
immediately take” and of DTG dispersible 5 mg tablets (5 
tablets) administered direct to mouth as compared to a 
conventional 25 mg tablet (reference) administered direct 
to mouth. Plasma DTG AUC (0-∞), AUC (0-t), and C max
Secondary
To compare the single dose PK of DTG dispersible 5 
mg tablets (5 tablets) administered as “disperse and 
immediately take” and of DTG dispersible 5 -mg tablets 
(5 tablets) administered direct to mouth as compared to 
a conve ntional 25 mg tablet (reference) administered 
direct to mouth.
To evaluate the safety and tolerability of DTG 
dispersible 5 -mg tablets (5 tablets) administered as 
“disperse and immediately take” and of DTG dispersible 
5-mg tablets (5 tablets) administered direct to mouth as 
compared to a conventional 25 mg tablet (reference) 
administered direct to mouth.Plasma DTG t lag, tmax, t, t ½, z, %AUC ex, AUC (0-24), CL/F 
and Vz/F, Ct, and C 24
Safety and tolerability parameters as assessed by 
[CONTACT_691721].   Palatability Questionnaire
2016N302761_00 CONFIDENTIA L
205893
175. STUDY DESIGN
5.1. Overall Design
This study  will be conducted as a 2-part, open -label ,randomized, cross- over design with
one group of subjects in Part 1 of the study randomized to receive each of 2 study  
treatments (A and B) over 2 dosing periods (see Figure 1) , and another group of subjects 
in Part 2 of the study  randomized to receive each of 3 study  treatments (C, D, and E) over 
3 dosing periods (see Figure 2
).  Subjects will participate in only  one part of the study .  
Parts [ADDRESS_938042] 7 ( -4 hours) day s between doses of stud y medication.
Note:   The -4 hours is an allowed tolerance window to the 7 day  washout and is to allow 
the study  site and subjects flexibility  in scheduling admission and d osing for subsequent 
treatment periods (i.e., treatment periods 2 and/or 3).
Figure 1 Study  Design –Part 1 of the StudyScreening 
(≤30 days)Treatment Period 1
Treatment A: 
or
Treatment B:  
Washout of 7 daysTreatment Period 2
Treatment A: 
or
Treatment B: Follow -up ([ADDRESS_938043] 
dose)
Figure 2 Study  Design –Part 2 of the Study
Treatment Period 1
Treatment C: 
or
Treatment D: 
or
Treatment E: Treatment Period 2
Treatment C: 
or
Treatment D: 
or
Treatment E: Treatment Period 3 
Treatment C: 
or
Treatment D: 
or
Treatment E: Screening 
(≤30 days)
Washout of 7 daysWashout of 7 daysFollow -up ([ADDRESS_938044] 
dose)
5.2. Treatment Groups and Duration
The study  treatments to be administered in Part 1 of the study  are:
Treatment A:  Conventional 10 -mg DTG tablet ([ADDRESS_938045] ) administered direct to 
mouth .
Treatment B:  Conven tional 50-mg DTG tablet (reference ) administered direct to 
mouth .
2016N302761_00 CONFIDENTIA L
205893
18Table 3 Part 1 –Two-Period Crossover
Sequence (Total N=1 4) Period 1 Period 2
1 (n= 7) A B
2 (n= 7) B A
The study  treatments to be administered in Part 2 of the study  are:
Treatment C:  5 -mg dispersible DTG tablet (5 tablets) administered as a dispersion
and immediately  take n(test 1).
Treatment D:  5 -mg dispersible DTG tablet (5 tablets) administered as direct to mouth
(test 2).
Treatment E:  Conventional [ADDRESS_938046] to mouth
(reference).
Table 4 Part 2 –Three -Period Crossover
Sequence ( Total N=24 ) Period 1 Period 2 Period 3
1 (n= 4) C D E
2 (n= 4) D E C
3 (n= 4) E C D
4 (n= 4) C E D
5 (n= 4) D C E
6 (n= 4) E D C
The total duration of participation for a subject participating in Part [ADDRESS_938047] dose of study  drug.  At Follow -up, m ale subjects with no ongoing adverse 
events ( AEs)or Vital Sign/L aboratory  measures of clinical concern may  be followed 
virtually  by [CONTACT_503371].
To ensure adequate washout, there will be at least 7 day s between dosing periods, with an 
allowance window of 4 hrs (i.e., 7 day s minus 4 hrs) to allow for flexibility  in scheduling 
subjects to dose at the clinic.
PK samples will be collected for 72 hrs after each dose of study  drug.
5.3. Number of Participants
Approxi mately  14 healthy  subjects (to achieve 12 completed subjects) will participate in 
Part 1 of the study , and approximately  24 subjects (to achieve 18 evaluable subjects) will 
participate in Part [ADDRESS_938048]’s last visit.
5.5. Scientific Rationale for Study  Design
This open -label, randomi zed, cross -over design is well- established for the evaluation of 
relative bioavailability of different oral dosage forms.  Randomization of the treatment 
sequences is an attempt to prevent bias.  The washout of 7 day s between dosing periods 
should eliminat e the possibility  of carry over of drug exposure from the previous dosing 
period.  In each part of the study ,there are appropriately  named “test” and “ reference ” 
study  treatments which will be evaluated for the relative bioavailabilit y comparisons.  
The s tudy is subject to the appropriate regulatory  approval and Ethics Committee 
approval, and will be listed on the website ClinicalTrials.gov.  No blinding or placebo 
control will be used, as these are not necessary  for the purposes of this study .
5.6. Dose Justif ication
The US Food and Drug Administration (FDA )-approved dose of DTG for treatment -
naive HIV -infected adult and pediatric patients 12 y ears and older (and 40 kilogram 
[kg]) is 50 mg once daily.  The adult dose is given as 1x50 mg tablet once daily .
Part1 of the study  will compare relative BA of five 10 -mg conventional tablets (test) to 
that of one 50 -mg conventional tablet (reference). For part 1, the approved adult dose of 
50 mg DTG conventional tablet is used as a reference to benchmark exposures with
paediatric formulations to what is safe and effective in adults. 
Part 2 of the study  will compare relative BA of five 5 mg dispersible tablets administered 
as “disperse and immediately  take” and of dispersible 5 mg tablets to be administered as 
“direct t o mouth” to that of a single 25 mg conventional tablet (reference) administered 
direct to mouth.  The 25 mg dose of DTG control dose used in Part 2 of this study  will 
accommodate the relative BA assessment of the two pediatric dosage forms and will 
require a dosing of only  five (5) [ADDRESS_938049] eligibility  is provided in the Investigator’s 
Brochure (see GlaxoSmithKline Document Number RM2007/[ZIP_CODE]/10 ).
6.1. Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, adverse events, 
and other pertinent information on the ViiV Healthcare inv estigational product or other 
study  treatment that may  impact subject eligibility  is provided in the Investigator’s 
Brochure [GlaxoSmithKline Document Number RM2007/[ZIP_CODE]/10 ]. 
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
AGE
1.Between [ADDRESS_938050] AND DIAGNOSI S INC LUDING DISEASE SEVERI TY
2.Health y as determined by [CONTACT_691722] a 
medical evaluation including medical history , physical examination, laboratory  tests 
and cardiac evaluation (history  and electrocardiogram [ ECG ]).
A subject with a clinical abnormality  or laboratory  parameter(s) which is/are not
specificall y listed in the inclusion or exclusion criteria, outside the reference range for the 
population being studied may  be included onl y if the investigator in consultation with the 
Medical Monitor agree and document that the finding is unlikely  to introduce additional 
risk factors and will not interfere with the study  procedures. 
WEI GHT
3.Body weight 50 kg for males and 45 kg for females and body  mass index (BMI) 
within the range 18.5 –31.0 kg/m2(inclusive)
SEX
4.Male or female
a.Non-reproductive potential defined as:
2016N302761_00 CONFIDENTIA L
205893
21Pre-menopausal females with one of the following:
Documented tubal ligation
Documented h ysteroscopic tubal occlusion procedure with follow -up 
confirmation of bilateral tubal occlusion 
Hysterectomy
Documented Bilateral Oophorectom y
Postmenopausal defined as 12 months of spontaneous amenorrhea [in 
questionable cases a blood sample with simultaneous follicle stimulating 
hormone (FSH) and estradiol levels consistent with menopause (refer to 
laboratory  reference ranges for confirmatory  levels)].  Females on hormone 
replacement therap y (HRT) and whose menopausal status is in doubt will be 
required to use one of the highl y effective contraception methods if they wish to 
continue their HRT during the stud y.  Otherwise, they must discontinue HRT to 
allow confirmation of post- menopausal status prior to study enrolment.
b. Reproductive potential and agrees to follow one of the options listed in the Modified 
List of Highl y Effective Methods for Avoiding Pregnancy in Females of 
Reproductive Potential (FRP) (se e Appendix 5[Section 12.5]) from [ADDRESS_938051] dose of stud y medication and until 2weeks after dosing with study  
medication and completion of the follow- up visit.
The investigator is responsible for ensuring that subjects understand how to properl y use 
these methods of contraception.
INFORMED CONSENT
5. Capable of giving signed informed consent as described in Section 12.3, which 
includes compliance with the requirements and restrictions listed in the consent form 
and in this protocol.
6.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
CONCURRENT CONDITIONS/MEDI CAL  HISTORY (INCLUDES LIVER 
FUNCTION AND QTDURATION CORRECTED FOR HEART RATE [QTc]
INTERVAL) 
1.ALT and bilirubin >1.5xULN (isolated bilirubin >1.5xUL N is acceptable if bilirubin 
is fractionated and direct bilirubin <35%).
2.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities
(with the exception of Gilbert's s yndrome or as ymptomatic gallstones). 
3.QT correction using Fridericia Formula (QTcF ) >450 Milliseconds (msec)
NOTES :
The QTc F is the QT interval corrected for heart rate according to Fridericia’s 
formula (QTcF) , machine -read or manually  over -read.
2016N302761_00 CONFIDENTIA L
205893
22The specific formula that will be used to determine eligibility  and 
discontinuation for an individual subject should be determined prior to initiation 
of the study . In other words, several different formulae cannot be u sed to 
calculate the QTc for an individual subject and then the lowest QTc value used 
to include or discontinue the subject from the trial.
For purposes of data analy sis, QTcF, will be used as specified in the Reporting 
and Anal ysis Plan (RAP).
CONCOMI TANT MEDICATIONS
4.Unable to refrain from the use of prescription (i.e., or non -prescription drugs, 
including vitamins, herbal and dietary supplements (including St John’s Wort) within 
7 day s (or 14 day s if the drug is a potential enzy me inducer) or 5 half -lives 
(whichever is longer) prior to the first dose of study  medication, unless in the opi[INVESTIGATOR_691703] y.
REL EVANT HABITS
5.History  of regular alcohol consumption within 6 months of the study  defined as:
An average weekl y intake of >14 drinks for males or >7 drinks for females. One 
drink is equivalent to 12 g of alcohol: 12 ounces (360 milliliters [ mL]) of beer, 5 
ounces (150 mL) of win e or 1.5 ounces (45 mL) of 80 proof distilled spi[INVESTIGATOR_2120].
6.Urinary  cotinine levels indicative of smoking or history  or regular use of tobacco- or 
nicotine -containing products within 1month prior to screening.
CONTRAINDICATIONS 
7.History  of sensitivity  to an y of the stud y medications, or components thereof or a 
history  of drug or other allergy  that, in the opi[INVESTIGATOR_427175], contraindicates their participation.
DIAGNOSTIC ASSESSMENTS AND OTHER CRI TERIA
8.Creatinine clearance (CrC L) <90 mL /min
9.A positive hepatitis B surface antigen (HBsAg) or a positive hepatitis B core antibody  
with a negative hepatitis B surface antibody , positive hepatitis C antibody  test result 
at screening or within [ADDRESS_938052] dose of study  treatm ent.
10.A positive pre -study  drug/alcohol screen.
11.A positive test for HIV antibody .
12.Where participation in the study would result in donation of blood or blood product in 
excess of [ADDRESS_938053] dosing day  in the current 
study : [ADDRESS_938054] (whichever is longer).
14.Exposure to more than four new chemical entities within [ADDRESS_938055] yle Restrictions
6.3.1. Meals and Dietary  Restrictions
Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice 
[and/or pummelos, exotic citrus fruits, grapefruit hy brids or fruit juices] from 7 day s prior 
to the firs t dose of study  medication until after the final dose.
Once in the clinical unit, subjects will not be allowed to eat an ything other than the food 
provided b y the study center.
6.3.2. Fasting Conditions
During the overnight period from Day  -1 to Day  1of each dosing period :
An evening meal and/or snack will be provided by [CONTACT_8508] (e.g. on Day  -1).
Subjects must then fast from all food and drink (except water) for 10 hr s pre -dose and 
prior to an y clinical laboratory evaluations (except repeat evaluations).
Water is permitted with dosing ( 200-250 mL) for all Treatment s except Treatment C 
andat all times except 1 hour ( hr)pre-dose through 2-hr s post -dose. 
No food is allowed for at least [ADDRESS_938056] for the stud y center.
6.3.4. Caffeine, A lcohol, and Tobacco
During each treatment period , subjects will abstain from ingesting caffeine -or xanthine -
containing products (e.g., coffee, tea, cola drinks and chocolate) for 24 hrs prior to the 
start of dosing until collection of the final PKand or pharmacody namic sample during 
each session. 
During each do
sing session, subjects will abstain from alcohol for 24 hrs prior to the start 
of dosing until collection of the final pharmacokinetic and or pharmacod ynamic sample 
during each session. 
Use of tobacco products is not allowed from 1 month prior to screenin g and until after the 
final follow -up visit.
6.3.5. Activity
Subjects will abstain from strenuous exercise for 48 hr s prior to each blood collection for 
clinical laboratory  tests.  Subjects may  participate in light recreational activities during 
studies (e.g., wa tch television, read).
6.4. Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  
but are not subsequentl y randomized/entered in the study . A minimal set of screen failure 
2016N302761_00 CONFIDENTIA L
205893
24information is required to ensure transparent reporting of screen failure participants to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory  authorities. Minimal information 
includes demograph y, screen failure det ails, eligibility  criteria, and any  serious adverse 
events (SAE s).
Individuals who do not meet the criteria for participation in this study  (screen failure) 
may notbe rescreened. 
7. TREATMENTS
Study  treatment is defined as an y investigational treatment(s), marketed product(s), 
placebo, or medical device (s)intended to be administered to a study  participant according 
to the study  protocol.
7.1. Treatments A dministered
Subjects in Part 1 of the study  will be randomized to one of the 2 following treatment 
sequences :ABorBA in accordance with the randomization schedule generated by  
[CONTACT_278814], prior to the start of the study , using validated software.  
Subjects in Part 2 of the study  will be randomized to one of the 6 following treatment 
sequences:  CDE , DEC, ECD , CED, DCE, or EDC in accordance with the randomization 
schedule generated b y Clinical Statistics, prior to the start of the study , using validated
software. 
Descriptions of the stud y treatments A and B in Part [ADDRESS_938057] name: [CONTACT_691727] ( DTG ) TIVICAY (DTG)
Dosage form: Conventional 10 mgDTG Tablet Conventional 50 mg DTG Tablet
Unit dose strength(s)/Dosage 
level(s):Single dose of five (5) 10 mgDTG 
tablets Single dose of one ( 1)50 mgDTG 
tablet
Route of Administration Oral Oral 
Dosing instructions: Treatment A:Take five (5) [ADDRESS_938058] to mouth with 240 
mL of water Treatment B:Take one (1) 50mg DTG 
tablet direct to mouth with 24 0 mL of 
water
Physical description: DTG (10 mg) tablets –White, round, 
biconvex tabletsDTG (50 mg) tablets –White, rou nd, 
biconvex tablets
Manufacturer: GlaxoSmithKline GlaxoSmithKline
Fasting instructions: Administer in the AM on an empty 
stomach.  Food will be unavailable 
until 4h after dose and water until 2h 
after dose.Administer in the AM on an empty 
stomach.  Foo d will be unavailable until 
4h after dose and water until 2h after 
dose.
2016N302761_00 CONFIDENTIA L
[ADDRESS_938059] name: [CONTACT_691727] (DTG) TIVICAY (DTG)
Dosage form: 5 mgDispersible DTG Tablet Conventional 25 mg DTG Tablet
Unit dose strength(s)/Dosa ge 
level(s):Single dose of five (5) 5mg DTG 
tablets Single dose of one (1) 25mg DTG 
tablet
Route of Administration Oral Oral 
Dosing instructions: Treatment C: Immediately take five (5) 
5 mg Dispersible DTG tablets 
administered as Dispersed in wate r
Treatment D:   Take five (5) [ADDRESS_938060] to mouthTreatment E:Take one (1) [ADDRESS_938061] to 
mouth
Physical description: DTG (5 mg) tablets –White, round, 
biconvex tabletsDTG ( 25 mg) tablets –White, round, 
biconvex tablets
Manufacturer: GlaxoSmithKline GlaxoSmithKline
Fasting instructions: Administer in the AM on an empty 
stomach.  Food will be unavailable 
until 4h after dose and water until 2h 
after dose.Administer in the A M on an empty 
stomach.  Food will be unavailable until 
4h after dose and water until 2h after 
dose.
7.1.1. Dosing Dispersible Tablets in Treatment C
Each dispersible tablet for Treatment C contains DTG 5 mgin strength; therefore, 
5tablets will be needed to ach ieve the [ADDRESS_938062] 25 mL of purified water in a small beaker / container.  A [ADDRESS_938063] 5 tablets into the beaker and swirl / stir for 3 – 3.5 minute s. The 
tablets should be fully  dispersed in approx imately 90 seconds, but swirling/stirring for 
the full time will guarantee dispersion.
3.Have the volunteer swallow the dispersion as swif tly as they  can,preferabl y in [ADDRESS_938064] the volunteer swallow this as swif tly as they are able ,
preferab ly in 1 to 2 swallows.
5.Give the volunteer an additional 190 mL of purified water to swallow .
NOTE :The words “immediatel y dose” in this protocol mean within one minute after 
completion of the 3 minute preparation. 
Anticipate that there will still be a limited amount of insoluble material visible in the 
beaker afte r thedispersion ha s been dosed and rinsed; this is normal and will not affect 
the dose delivered.
7.2. Blinding
This is an open -label study ; potential bias will be reduced b y arandomization of 
treatments provided to the site pharmacist.
2016N302761_00 CONFIDENTIA L
205893
267.3. Preparation/Handling/S torage/A ccountability
The tablets are packaged into high -densit y polyethylene (HDPE) bottles.  Each bottle of 
DTG [ADDRESS_938065] tablets 
from moisture.
The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolved before use of the stud y treatment.
Only  subjects enrolled in the study  may  receive study  treatment and onl y authorized 
site staff may  supply  or administer study  treatment.  All st udy treatments must be 
stored in a secure environmentally  controlled and monitored (manual or automated) 
area in accordance with the labelled storage conditions with access limited to the 
investigator and authorized site staff. 
The investigator, instituti on, or the head of the medical institution (where applicable) 
is responsible for stud y treatment accountability, reconciliation, and record 
maintenance (i.e. receipt, reconciliation and final disposition records).  
Further guidance and information for fin al disposition of unused study  treatment are 
provided in the Study  Reference Manual.
TIVICAY tablets are to be stored at 15-30C and protected from light.  Maintenance 
of a temperature log (manual or automated) is required.
Under normal conditions of hand ling and administration, study treatment is not 
expected to pose significant safety risks to site staff .  
A Material Safety  Data Sheet (MSDS )/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investigator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
7.4. Treatment Compliance
When subjects are dosed at the site, they  will receive study  treatment directly  from the 
investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic will be recorded in the source documents.  The dose of study  
treatment and study subject identification will be confirmed at the time of dosing b y a 
member of the stud y site staff other than t he person administering the study treatment.  
Study  site personnel will examine each subject’s mouth to ensure that the study  treatment 
was ingested.
7.5. Concomitant Therapy
Subjects must abstain from taking an y other prescription and non -prescription drugs 
including vitamins, herbal and dietary supplements (including St John’s Wort), within 7 
days (or 14 day s if the drug is a potential enz yme inducer) or 5 half- lives (whichever is 
longer) prior to the first dose of study  medication until completion of the foll ow-up visit, 
2016N302761_00 CONFIDENTIA L
[ADDRESS_938066] safet y.
Use of antacids, vitamins, and iron supplements are strictly  prohibited within 7 day s (or 
14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is longer) 
prior to the first dose of study  medication and for the duration of the trial, including 
follow -up.
Acetaminophen, at doses of 2 grams/day ,is permitted for use any time during the study.  
Other concomitant medication may  be considered on a case by  [CONTACT_691723] .
7.6. Treatment at the End of the Study
This is a single dose study , there will be no treatment at the end of the study .
8. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
8.1.1. Liver Chemistry Stoppi[INVESTIGATOR_131957] y and evaluate liver event etiology (in al ignment with the FDA 
premarketing clinical liver safety  guidance). 
NOTE :  Although this is a single -dose study , please use the following as guidance.
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
2016N302761_00 CONFIDENTIA L
[ADDRESS_938067] if liver chemistry  stoppi[INVESTIGATOR_190725]:
Phase I Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_589341]  
*INR value not applicable to subjects on anticoagu lants ALT ≥3xULN No
Yes
Must  refer to Liver Safety Required Actions and Fol low up Asses sments  section in the Appendi x
Repor t as an SAE if possible Hy’sLaw case:  ALT≥3xUL N and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5 , if measur ed*
Liver Safet y Required Actions and Follow up Assessments Section can be found in 
Appendix 2(Section 12.2).
Study Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_496917].
8.1.2. QTc Stoppi [INVESTIGATOR_2121]
A subject that meets the following bulleted criterion below will be withdrawn from the 
study .  
QTcF >500 msec
NOTES :
The same QT correction formula must be used for each individual subject to 
determine eligibility  for and discontinuation from the study .  This formula may  not be 
changed or substituted once the subject has been enrolled.
For example, if a subject is eligible for the protocol based on QTcF, then QTc Fmust 
be used for discontinuation of this individual subject as well.
Once the QT correction formula has been chosen for a subject’s eligibility , the same 
formula must continue to be used for that subject for all QTc data being collected for 
data analysis .  Safety  ECGs and other non- protocol specified ECGs are an exception.  
2016N302761_00 CONFIDENTIA L
205893
29 The QTc s hould be based on averaged QTc values of triplicate ECG s obtained over a 
brief (e.g., 5 -10 minute) recording period.  
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  
be withdrawn at an y time a t the discretion of the investigator or Sponsor for safet y, 
behavioral, compliance or administrative reasons.
If after screening, the subject requires concurrent medications that cannot be 
interrupted for [ADDRESS_938068] and until 
completion of the study .
Pregnancy
Positive urine drug or alcohol screen.
Any clinically  significant AE deemed to require discontinuation of investigational 
product .
If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any  data collected before such a withdrawal of 
consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site study  
records.
Refer to the Table 2for data to be collected at the time of study  discontinuation and
follow -up and for an y further evaluations that need to be completed.
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must a ttempt to contact [CONTACT_288949]/or 
should continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_14316]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary  reason of lost to follow -up. 
2016N302761_00 CONFIDENTIA L
[ADDRESS_938069] reasons for 
screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (e .g., blood 
count) and obtained before signing of informe d consent form ( ICF)may be utilized for 
screening or baseline purposes provided the procedure met the protocol -specified criteria 
and was performed with in the time frame defined in Table 2.
The following points must be noted: 
Ifassessments are scheduled for the same nominal time, THEN the assessments 
should occur in the following order:
1. 12 -lead ECG
2.vital signs
3.blood draws.  
Note: The timing of the assessments should allow the blood draw to occur at the exact 
nominal time.
The t iming and number of planned study  assessments, including safet y, PK or other
assessments may  be altered during the course of the study  based on newl y available 
data (e.g., to obtain data closer to the time of peak plasma concentrations) to ensure 
appropria te monitoring. 
The change in timing or addition of time points for any  planned study assessments 
must be documented in a Note to File which is approved b y the relevant [COMPANY_004] study  
team member and then archived in the study  sponsor and site study  files, but this will 
not constitute a protocol amendment. 
The Institutional Review Board (IRB)/ Independent Ethics Committee ( IEC) will be 
informed of an y safety issues that require alteration of the safet y monitoring scheme 
or amendment of the Informed Consent Form . 
No more than 500 mL of blood will be collected over the duration of the study , 
including an y extra assessments that may  be required.
2016N302761_00 CONFIDENTIA L
205893
319.1. Adverse Events
The definitions of an AE or SAE can be found in Appendix 4 .
The investigator and a ny designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AE sthat are serious, considered related to the study  treatment or the study ,
or that caused the participant to discontinue the study (see Section 8). 
9.1.1. Time Period and Frequency  for Collecting A E and SA E 
Information
Any SAEs assessed as related to study  participation (e.g., protocol- mandated 
procedures, inv asive tests, or change in existing therapy ) or related to a [COMPANY_004] product 
will be recorded from the time a subject consents to participate in the stud y up to and 
including an y follow -up contact. 
 AEswill be collected from the start of treatment until the follow -up visit at the 
time points specified in Table 2 (Section 2).
 Medical occurrences that begin before the start of study  treatment but after 
obtaining informed consent will be record ed on the Medical History /Current Medical 
Conditions section of the electronic case report form ( eCRF) not the AE section.
 All SAE swill be recorded and reported to th e sponsor or designee within 
24hours, as indicated in Appendix 4 .The investigator will submit any  updated SAE 
data to the sponsor within 24 hours of it being available.
 Investigators are not obligated to activel y seek AEs or SAEs in former study  
participants. However, if the investigator learns of any SAE, including a death, at any  
time after a participant has been discharged from the study , and he/she considers the 
event to be reasonabl y related to the study  treatment or study  participation, the 
investigator must promptly  notify  the sponsor.
 The method of recording, ev aluating, and assessing causality  of AEs and SAEs
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 4 .
9.1.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AE and/or SAE. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrence.   Appropriate questions include:
“How are you feeling
“Have you had an y (other) medical problems since y our last visit/cont act
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?” 
2016N302761_00 CONFIDENTIA L
205893
329.1.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent vi sits/contacts. All SAEs, and non-serious AEs ,will be 
followed until the event is resolved, stabilized, otherwise explained, or the participant is 
lost to follow -up (as defined in Section 8.3). Further informat ion on follow -up 
procedures is given in Appendix 4 (Section 12.4).
9.1.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so that 
legal obl igations and ethical responsibilities towards the safet y of participants and the 
safet y of a stud y treatment under clinical investigation are met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  treatment under clinical 
investigation. The sponsor will comply  with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory  requirements and sponsor policy  and 
forwarded to investigators as necessary .
An inves tigator who receives an investigator safety report describing a SAE or other 
specific safet y information, e.g., summary  or listing of SAE) from the sponsor will 
review and then file it along with the Investigator’s Brochure (GlaxoSmithKline 
Document Number RM2007/[ZIP_CODE]/10 ) and will notify  the IRB/IEC, if appropriate 
according to local requirements.
9.1.5. Pregnancy
Details of all pregnancies in all female subjects will be collected after the start of dosing 
and until the final post-dose follow -up visit .
If a pregnancy  is reported then the investigator should inform [COMPANY_004] within 2 weeks of 
learning of the pregnancy  and should follow the procedures outlined in Section 12.5.2 of 
Appendix 5.
Abnormal pregnancy  outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
9.2. Treatment of Overdose
In Part 1 of this study ,any single dose of DTG >50 mg will be considered an overdose.  
In Part 2 of this study , any  single dose of DTG>25 mg will be considered an overdose.
ViiV does not recommend specific treatment for an overdose of DTG. The investigator 
will use clinical judgment to treat an y overdose.
In the event of an overdose,the investigator or treating ph ysician should:
1.Contact [CONTACT_27465]
2016N302761_00 CONFIDENTIA L
[ADDRESS_938070] for AEs)/ SAEs and laboratory  abnormalities until DTG 
can no longer be detected sy stemicall y (at least 7 day s).
3. O btain a plasma sample for PK anal ysis within 2days from the date of the last dose 
of study  treatment if requested by  [CONTACT_1689] (determined on a case -by-case 
basis).
4. D ocument the quantity of the excess dose as well as the duration of the overdosing in 
the eCRF.
9.3. Safet yAssessments
Planned time points for all safety  assessments are provided in Table 2 .
9.3.1. Physical Examinations
A fullphysical examination , if needed, will include, at a minimum, assessments of 
the head, ey es, ears, nose, throat, skin, thy roid, neurological, lungs, cardiovascular, 
abdomen (liver and spleen), ly mph nodes and extremities . Height and weight will also 
be measured and recorded. 
A brief ph ysical examination will include, at a minimum , assessments of the skin, 
lungs, cardiovascular s ystem, and abdomen (liver and sp leen).
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses
9.3.2. Vital Signs
Vital signs will be measured in supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_55848] [ADDRESS_938071] 
and will incl ude temperature, s ystolic and diastolic blood pressure (BP) and pulse 
rate.
9.3.3. Electrocardiograms
12-lead ECGs will be performed with the subject in a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_691704] 5minutes beforehand
Single 12-lead ECGs will be obtained at screening and on Day  -[ADDRESS_938072] experiences a 
QTcF >500 msec, r eferto Section 8.1.2 for QTcF withdrawal criteria and repeat 2 
ECG recordings over a brief (e.g., 5 -10 minute) period (i.e., additional QTcF readings
that may  be necessary ).
9.3.4. Clinical Safety  Laboratory  Assessments
All protocol requ ired laboratory  assessments, as defined in Table 5, must be conducted in 
accordance with the Laboratory  Manual, and Protocol Time and Events Sche dule in the 
SoA for the timing and frequency .Laboratory  requisition forms must be c ompleted and 
samples must be clearl y labelled with the subject number, protocol number, site/centre 
number, and visit date. Reference ranges for all safety parameters will be provided to the 
site by  [CONTACT_90633].
2016N302761_00 CONFIDENTIA L
205893
34If addit ional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in subject management or are 
considered clinically  significant by  [CONTACT_093] (e.g., SAE or AE or dose 
modification) the res ults must be recorded in the eCRF.
Refer to the Study  Reference Manual (S RM)/BioPacket for appropriate processing and 
handling of samples to avoid duplicate and/or additional blood draws.
Haematology , clinical chemistry , urinal ysis and additional paramet ers to be tested are 
listed in Table 5
.
Table 5 Protocol Required Safety  Laboratory  Assessments
Laboratory 
AssessmentsParameters
Haematology Platelet Count RBC Indices White blood cell (WBC) count with 
Differential :
Hematocrit Mean corpuscular 
hemoglobin (MCH)
Mean corpuscular 
volume (MCV)Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsHemoglobin
Red blood cell Count (RBC) 
WBC Count (absolute)
Clinical 
ChemistryaBlood urea n itrogen 
(BUN)Potassium AST ( serum glutamic 
oxaloacetic 
transaminase [ SGOT ])Total and direct bilirubin
Creatinine Sodium ALT ( serum glutamic 
pyruvic transaminase 
[SGPT ))Total Protein
Glucose Calcium Alkaline phosphatase Albumin
Creatine 
phosphokinase 
(CPK)
Routine 
Urinalysis Specific gravity
 pH, glucose, protein, blood and ketones by [CONTACT_5230]
 Microscopic examination (if blood or protein is abnormal)
Other Screening 
and/or Additional 
Tests (see
Section 2for 
timing of these 
Assessments) HIV
 Hepatitis B (HBsAg)
 Hepatitis B core antibody 
 Hepatitis C (Hep C antibody)
 FSH and estradiol (as needed in women of non -child bearing potential only)
 Alcohol and drug screen (to include at minimum: amphetamines, b arbiturates, cocaine, 
opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651])b
 Cotinine
 Creatinine clearance (CrCL) for glomerular filtration rate(GFR )estimation 
 Serum or urine human chorionic gonadotropin hCG Pregnancy test (as needed for women 
of child bearing pot ential)b
 The results of each test must be entered into the eCRF.
NOTES :
a Details of Liver Chemistry Stoppi[INVESTIGATOR_131963] -Up Assessments after liver stoppi[INVESTIGATOR_43191] 8.1.[ADDRESS_938073] dose of study  treatment 
should be repeated until the values return to normal or baseline (at the discretion of the 
Investigator and Medica l Monitor) .  If such values do not return to normal within a period 
judged reasonable b y the investigator, the etiology should be identified and the S ponsor 
notified.
9.4. Pharmacokinetics
9.4.1. Blood Sample Collection
Blood samples for PK analy sis of DTG will be col lected at the time points indicated in
the Time and Events Table.  The actual date and time of each blood sample collection 
will be recorded.  Blood specimens (2 mL) will be collected into K 2
ethylenediaminetetraacetic acid ( EDTA )tubes. 
Details of PK blo od sample collection, Windows of Allowance, processing, storage and 
shippi[INVESTIGATOR_691705]/BioPacket .
9.4.2. Sample A nalysis
Plasma analy sis will be performed under the control of Platform Technology  and Science 
(PTS), GlaxoSmit hKline, the details of which will be included in the Study  Reference 
Manual ( BioPacket ).Concentrations of DTG will be determined in plasma samples 
using the currentl y approved bioanal ytical methodology .Raw data will be archived at 
the bioanal ytical site ( detailed in the SRM/BioPacket ).
Once the plasma has been anal yzed for drug concentrations any  remaining plasma may 
be anal yzed for other compound -related metabolites and the results reported under a 
separate PTS, GlaxoSmithKline protocol.
9.5. Formulation Pa latability  Assessment
A palatability  questionnaire will be administered to each subject in Treatment Arm C
within 10 minutes foll owing dosing of dispersion t reatments onl y, see Appendix 8
(Section 12.8).  Subjects will be given the questionnaire to read prior to receiving each 
unique dispersion dose.
10. STATISTICA L CONSIDER ATIONS
10.1. Hypotheses
This study  is designed to estimate the relative bioavailability  of each test treatment to the 
reference treatment (A vs. B; C vs. E and D vs. E) in both study  parts in the fasted state.
No formal h ypothesis will be tested. For each pharmacokinetic endpoint (except for time 
of occurrence of Cmax [t max]and t lag), point estimates and corresponding 90% confidence 
intervals wil l be constructed for the ratio of the geometric mean of the test treatment to 
the geometric mean of the reference treatment, µ(test)/µ(reference).
2016N302761_00 CONFIDENTIA L
[PHONE_14363].2. Sample Size Considerations
10.2.1. Sample Size A ssumptions
Based on the results from a previous PK study  of dolutegra vir granules administered to 
healthy volunteers, [GlaxoSmithKline Document Number 2011N124158_00], the within -
subject variability  (CV w%) of dolutegravir area under the plasma concentration -time 
curve from time of dose extrapolated to infinity (AUC (0-))and maximum observed 
concentration (Cmax)ranged from 15.0% to 16.2%. Therefore, it isdecided that 16.2% 
would be a conservative estimate on which the sample size calculation is based.
For Part 1, w ith a sample size of 12 evaluable subjects (6 subjects/sequence), it is 
estimated that the precision (i.e. half -width of the 90% confidence interval ( CI)on the 
ratio scale) for the test: reference comparison will be within 13% of the point estimate for 
AUC (0-)and C max.  Hence, if the point estimate of the ratio of geometric means is 1 then 
the 90% confidence interval (CI) will be approximately  (0.89, 1.13).
For Part 2, w ith a sample size of 18 subjects (at least 3 subjects/sequence), it is estimated 
that the precision (i.e. half -width of the 90% CI on the ratio scale) for the test: reference 
comparison will be within 10 % of the point estimate for AUC (0-)and C max.  Hence, if the 
point estimate of the ratio of geometric means is 1 then the 90% CIwill be approximately  
(0.91, 1.10).
10.2.2. Sample Si ze Sensitivity
For the sensitivity  anal ysis, assuming ahigher within -subject variability  (24%) , a sample 
size of 12 evaluable subjects in Part 1, it is estimated that the half width of the 90% CI for 
the ratio of treatment comparison (test : reference) wo uld be within 1 9% of the point 
estimate for AUC (0-)and C max.  A sample size of 18 evaluable subjects in Part 2, it is 
estimated that the half width of the 90% CI for the ratio of treatment comparison 
(test:reference) would be within 14% of the point estimate f or AUC (0-∞)and C max. 
10.2.3. Sample Size Re -estimation
No sample size re -
estimation will be performed.
10.2.4. Analysis Populations
Subjects excluded from any anal yses will be full y documented and justified within the 
clinical study  report. All anal yses will be ba sed on the actual treatment that each subject 
received. An y departures from the planned treatment according to the randomization 
schedule will be documented in the clinical study  report.
The following populations will be used for the analysis and reporting of data:
2016N302761_00 CONFIDENTIA L
205893
37All Subjects Population
The ‘All Subjects Population’ is defined as all subjects who receive at least one dose of 
study  medication. This population will be used for all demographic and safety  
summaries.
Pharmacokinetic (PK) Population
The ‘PK P opulation' is defined as subjects in the ‘All Subjects’ population for whom a 
PK sample was obtained and had evaluable PK assay  results. PK samples that may  be 
affected b y protocol deviations will be reviewed by [CONTACT_43038] y team to determine whether 
or not t he sample will be excluded. This population will be used for reporting of PK data.
10.2.5. Interim A nalyses
There will be no formal interim anal ysis.
10.3. Key Elements of A nalysis Plan
Final anal yses will be performed after the completion of the study  and final datab ase 
authorization.  
Data will be listed and summarized according to GlaxoSmithKline reporting standards 
where applicable. Listings will be sorted by  [CONTACT_1130], period, day , and time, noting 
treatment. Summaries will be presented b y treatment, day  and time. 
Unless stated otherwise, descriptive summaries for continuous variables will include n, 
mean, standard deviation (SD), median, minimum, maximum ; whereas, n and percent 
will be used as summary  statistics for categorical variable. Geometric mean with 
associ ated 95% CI, and the between -subject coefficient of variance ( CV)(%CVb) for the 
geometric mean will be included for PK variables, where applicable.
Baseline or pre -dose assessment is the last available assessment prior to time of the first 
dose unless it is specified otherwise.  If there are multiple assessments collected on the 
same scheduled time, the average of these assessments will be used.  For tabulated safet y 
summaries, only  the scheduled assessments will be included in the summary  tables.
Version 9.4 or higher of the Statistical Analy sis Software (SAS) system will be used to 
analyze data as well as to generate tables, listings, and figures.
10.3.1. Primary  Analyses
[IP_ADDRESS]. Pharmacokinetic Analyses
Pharmacokinetic anal yses will be the responsibility  of the Clinical Pharmacology  
Modeling & Simulation department within [COMPANY_004] or their designee.  Plasma DTG 
concentration -time data will be anal yzed by [CONTACT_105] -compartmental methods with Phoenix 
WinNonlin .  Calculations will be based on the actual sampling times recorded during the 
study .  From the plasma concentration- time data, the following PKparameters will be 
determined, as data permit:  AUC (0-), area under the plasma concentration -time curve 
2016N302761_00 CONFIDENTIA L
[ADDRESS_938074] measurable concentration ( AUC (0-t)), area under the pla sma 
concentration -time curve from time of dose to 24 hr (AUC 0-24), C max,plasma DTG lag 
time for absorption (tlag), time of occurrence of Cmax (t max), terminal elimination phase 
half-life(t1/2), terminal rate constant (z), % of AUC (0-∞)that was extrapolated
(%AUCex ), apparent oral clearance (CL/F)and apparent volume of distribution during
terminal phase (Vz/F ), last quantifiable concentration ( Ct), and c oncentration at 24 hours 
after dose administration (C 24).
Pharmacokinetic data will be listed and may  be presented in graphical form and will be 
summarized descriptively.  All PK data will be stored in t he Archives, GlaxoSmithKline 
Research and Development (R& D). 
The PK parameters (except for t maxand t lag) for DTG will be log e-transformed and 
separately  anal yzed using a mixed effects model with fixed effect terms for period and 
treatment for each treatment comparison .  Subject will be treated as a random effect in 
the model.  Point estimates and their associated 90% CI s will be con structed for the 
differences in PK parameter values between test and reference treatments.  The point 
estimates and their associated 90% CIs will then be back -transformed to provide point 
estimates and 90% CIs for the ratios of PK parameters between test a nd reference 
treatments.
Further details will be provided in the Regulatory  Analy sis Plan (RAP).
[IP_ADDRESS]. Safety Analyses
Safety  data will be presented in tabular format and summarized descriptively  according to 
[COMPANY_004]’s Integrated Data Standards Library  (IDSL) standa rds.  No formal statistical 
analysis of the safety  data will be conducted.
The details of the statistical anal yses of safety  and PK data will be provided in the RAP .
10.3.2. Palatability  Questionnaire
Palatability  questionnaire variables will be summarized descrip tively . Further details will 
be provided in the RAP.
2016N302761_00 CONFIDENTIA L
[PHONE_14364]. REFERENCES
GlaxoSmithKline Document Number RM2007/[ZIP_CODE]/10 : [COMPANY_004]1349572 Clinical 
Investigator's Brochure. 10October [ADDRESS_938075] 
of different types of water plus i nfant f ormula on the pediatric granule formulation in 
healthy  male and female volunteers (ING114556) ; February  2012.
2016N302761_00 CONFIDENTIA L
[PHONE_14365]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
AE Adverse Event
AIDS Acquired immune deficiency syndrome
ALT Alanine aminotransferase (SGPT)
ART Antiretroviral Therapy
AST Aspartate aminotransferase (SGOT)
AUC Area under the concentration -time cur ve
AUC (0-t) Area under the plasma concentration -time curve from time of dose to last measurable 
concentration
AUC (0-) Area under the plasma concentration -time curve from time of dose extrapolated to infinity
AUC (0-24) Area under the plasma concentratio n-time curve from time of dose to 24 hr
%AUCex % of AUC (0-∞)that was extrapolated
BA Bioavailability
BMI Body mass index
BP Blood pressure
BUN Blood urea nitrogen
C24 Concentration at 24 hours after dose administration
CI Confidence Interval
CL/F Apparent oral clearance
Cmax Maximum observed concentra tion 
C24 Observed concentration at 24h post -dose
CNS Central nervous system
CONSORT Consolidated Standards of Reporting Trials
CPK Creatine phosphokinase
CrCL Creatinine Clearance
CRF Case Report Form
CV Coefficient of variance
CVb Between subject coefficient of variation
DAIDS Division of Acquired Immunodeficiency Syndrome
DILI Drug -Induced Liver Injury
DTG Dolutegravir
ECG Electrocardiogram
EDTA Ethylenediaminetetraacetic acid
EU European Union
FDA Food and Drug Administration
FRP Females of Reproductive Potential
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GFR Glomerular Filtration Rate
[COMPANY_004] GlaxoSmithKline
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
hCG Human chorionic gonadotropin
HCV Hepatitis C virus
HIV Human Immunodeficiency Virus
h/hr Hour(s)
HRT Hormone Replacement Therapy
HSR Hypersensitivity Reaction
IB Investigator’s Brochure
2016N302761_00 CONFIDENTIA L
[ADDRESS_938076] Organic cation transporter
PK Pharmacokinetic(s)
PTS Platform Technology and Science
QTc QT duration corrected for heart rate
QTcF QT correct ion using Fridericia Formula
R&D Research and Development
RAP Reporting and Analysis Plan
RBC Red blood cells
RNA Ribonucleic acid
SAE Serious adverse event(s)
SAS Statistical Analysis Software
SD Standard deviation
SGOT Serum glutamic oxaloacetic t ransaminase
SGPT Serum glutamic pyruvic transaminase
SJS Stevens -Johnson syndrome
SOP Standard Operating Procedure
SRM Study Reference Manual
t½ Terminal elimination phase half -life
TEN Toxic epi[INVESTIGATOR_691706]/ [LOCATION_003] [LOCATION_002] (of America)
WBC White blood cells
WCBP Women of Child Bearing Potential
Vz/F Apparent V olume of Distribution During Terminal Phase
z Terminal R ate Constant
Trademark Information
Trademarks of the ViiV group of companies Trademarks not owned by [CONTACT_691724]
2016N302761_00 CONFIDENTIA L
[PHONE_14366].2. Appendix 2: Liver Safety  Required A ctions and Follow up 
Assessments
Phase I Liver chemistry  stop pi[INVESTIGATOR_691707]  (in alignment with the FDA premarketing clinical liver 
safet y guidance).
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM 174090.pdf.
Phase I liver chemistry stoppi[INVESTIGATOR_90566] –Liver Stoppi[INVESTIGATOR_53053]-absoluteALT≥3xULN
If ALT ≥3xULN AND bilirubin1,22xULN (>35% direct bilirubin) or  International Normalized 
Ratio ( INR)>1.5, Report as an SAE.
See additional Actions and Follow Up Assessments listed below
Required Actions and Follow up Assessments following Liv er Stoppi[INVESTIGATOR_90567]
 Immediately discontinue study treatment 
 Report the event to [COMPANY_004] within 24 hours
 Complete the liver event eCRF, and complete an SAE 
data collection tool if the event also meets the criteria 
for an SAE2
 Perform liver event follow up assessments 
 Monitor the subject until liver chemistries resolve, 
stabilise, or return to within baseline (see 
MONITORING below)
MONITORING:
If ALT ≥3xULN AND bilirubin 2xULN or INR >1.5
 Repeat liver chemistries (include ALT, AST, alkaline 
phosphatase, bilirubin) and perform liver event follow 
up assessments within  24 hrs
 Monitor subjects twice weekly until liver chemistries 
resolve, stabilis e or return to within baseline
 A specialist or hepatology consultation is 
recommended
If ALT≥3xULN AND bilirubin < 2xULN and INR ≤1.5:
 Repeat liver chemistries (include ALT, AST, alkaline 
phosphatase, bilirubin) and perform liver event follow 
up assessment s within 24- 72 hrs
 Monitor subjects weekly until liver chemistries 
resolve, stabilize or return to within baseline Viral hepatitis serology3
 Blood sample for pharmacokinetic (PK) analysis, 
obtained within [ADDRESS_938077] dose.
 Serum creatine phosphokinase (CPK) and lactate 
dehydrogenase (LDH).
 Fractionate bilirubin, if total bilirubin 2xULN
 Obtain complete blood count with differential to 
assess eosinophilia
 Record the appearance or worsening of clinical 
symptoms of liver injury, or hypersensitivity, on th e 
AE report form
 Record use of concomitant medications on the 
concomitant medications report form including 
acetaminophen, herbal remedies, other over the 
counter medications.
 Record alcohol use on the liver event alcohol intake 
case report form
If ALT ≥3xULN AND bilirubin  2xULN or NR >1.5:
 Anti-nuclear antibody, anti- smooth muscle antibody, 
Type 1 anti -liver kidney microsomal antibodies, and 
quantitative total immunoglobulin G (IgG or gamma 
globulins).
 Serum acetaminophen adduct HPLC assay 
(quantifies po tential acetaminophen contribution to 
liver injury in subjects with definite or likely 
acetaminophen use in the preceding week [ James , 
2009].
 Liver imaging (ultrasound, magnetic resonance, or 
computerised tomography) a nd /or liver biopsy to 
evaluate liver disease; complete Liver Imaging 
and/or Liver Biopsy eCRF forms.
2016N302761_00 CONFIDENTIA L
[ADDRESS_938078] if ALT 3xULN andbilirubin 2xULN. 
Additionally, i fserum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting li ver injury. 
2. Allevents of ALT  3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT  3xULN andINR>1.5, if INR 
measured , which may indicate severe liver injury (possible ‘Hy’s Law’ ), must be reported as an SAE (excluding 
studies of hepatic impairm ent or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to subjects receiving anticoagulants
3. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
Appendix [ADDRESS_938079] in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
2016N302761_00 CONFIDENTIA L
[PHONE_14367].3. Appendix 3: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethi cal Guidelines
Applicable International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use ( ICH)Good 
Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an I RB/IEC by  [CONTACT_55892]/IEC before the study  is initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes necessary to 
eliminate an immediate hazard to study  participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of t he study  to the IRB/IEC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as required by 
[CONTACT_1744]/IEC procedures
Providing oversi ght of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations
Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y earafter completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the s tudy to the 
participant or his/her legally  authorized representative and answer all questions 
regarding the stud y. 
2016N302761_00 CONFIDENTIA L
205893
45Participants must be informed that their participation is voluntary . Participants or 
their legally  authorized representative will be require d to sign a statement of informed 
consent that meets the requirements of [ADDRESS_938080] (HIPAA) requirements, where 
applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
Partici pants must be re -consented to the most current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or an y informatio n which would make the participant identifiable 
will not be transferred. 
The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_10999]. The level of disclosure 
must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  
[CONTACT_171138], by  [CONTACT_6667]/IEC members, and by  [CONTACT_55894].
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission. This allows the sponsor to protect proprietary  information 
and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support publi cation of multi- center studies onl y in their entiret y and not as individual 
site data. In this case, a coordinating investigator [INVESTIGATOR_159828] b y mutual 
agreement.
Authorship will be determined by  [CONTACT_11403] I nternational 
Committee of Medical Journal Editors authorship requirements.
2016N302761_00 CONFIDENTIA L
205893
46Dissemination of Clinical Study  Data
Data Quality  Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee elect ronically  (eg, laboratory  data). The 
investigator is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically  signing the eCRF. 
The investigator must maintain accurate documentation (source data) that supports 
the information entered in the eCRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
The sponsor or designee is responsible for the data m anagement of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the eCRF b y authorized site personnel are accurate, complete, and 
verifiable from source documen ts; that the safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this study  
must be retained b y the investigator for 25years from the issue of the final Clinical 
Study  Report (CSR)/ equivalent summary unless local regulations or institutional 
policies require a longer retention period. No records may  be destroy ed during the 
retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. 
Source Documents
Sourc e documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the eCRF or entered in the eCRF that are transcribed from source
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitu tes source data can be found in the SRM.
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be close d upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
2016N302761_00 CONFIDENTIA L
205893
47The investigator may  initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply with the protoco l, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines .
Inadequate recruitment of participants b y the investigator.
Discontinuation of further study  treatment development .
2016N302761_00 CONFIDENTIA L
[PHONE_14368].4. Appendix 4: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study treatment, whether or not co nsidered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered cli nicall y significant in the medical 
and scientific judgment of the investigator (ie, not related to progression of underly ing 
disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even though it 
may have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mpto ms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdo ses should be reported regardless of sequelae.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that leads to 
the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
2016N302761_00 CONFIDENTIA L
205893
49convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-dayfluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, h ospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the phy sician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct normal 
life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, an d 
accidental trauma (eg, sprained ankle) which may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may  not be 
immediately  life-threatening or result in death or hospi[INVESTIGATOR_160340]. These events should usually  be considered 
serious.
2016N302761_00 CONFIDENTIA L
205893
50Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency  room or at home for alle rgic bronchospasm, blood dy scrasias or convulsions 
that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  or drug abuse.
Recording A E and SA E
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to re view all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) related to 
the event.
The investigator will then record all relevant AE/SAE information in the eCRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAE e CRF page.
There may  be instances when copi[INVESTIGATOR_691708] . In this case, all participant identifiers, with the exception of the participant number, 
will be redacted on the copi[INVESTIGATOR_333205] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diag nosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort and 
not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
every day activities.
Severe: An event that pre vents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category  utilized for rating the 
intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and each 
occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
The investigator will use clinical judgment to determine the re lationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other risk 
2016N302761_00 CONFIDENTIA L
205893
51factors, as well as the temporal relationship of the event to study  treatment administration 
will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of ca usalit y.
There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to [COMPANY_004] . However, it is very important that 
the investigator always make an assessment of causality for every event b efore the 
initial transmission of the SAE data to [COMPANY_004] .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
If a participant dies during participation in the study  or during a recognized follow -up 
period, the investigator will provide [COMPANY_004] with a copy  of any  post -mortem findings 
including histopathology .
New or updated information will be recorded in the originally  completed eCRF.
The investigator will submit any  updated SAE data to [COMPANY_004] within 24 hours of receipt of 
the information.
Reporting of SA E to [COMPANY_004] /ViiV
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic d ata collection 
tool.
If the electronic s ystem is unavailable for more than 24 hours, then the site will use the 
paper SAE data collection tool (see next section).
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
The investigator or medically -qualified sub -investigator must show evidence within the 
eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to I P/study  participation (causalit y) within 72 hours of SAE 
2016N302761_00 CONFIDENTIA L
205893
52entry into the eCRF.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or r eceives updated data 
on a previousl y reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this information on a paper SAE fo rm (see next section) or to 
the Medical M onito rby [CONTACT_756].
Contacts for SAE r eporting can be found in the Medical Monitor Name [CONTACT_9352] 
[CONTACT_691725].
2016N302761_00 CONFIDENTIA L
[PHONE_14369].5. Appendix 5: Modified List of Highly  Effective Methods for 
Avoiding Pregnancy  in FRP and Collection of Pregnancy  
Information
12.5.1. Modified List of Highly Effective Methods for Avoiding Pregnancy  
in Females of Reproductive Potential (FRP)
The list does not apply  to FRP with same sex partners or for subjects who are and will 
continue to be abstinent from penile-vaginal intercourse on a long term and persistent 
basis, when this is their preferred and usual lifest yle. Periodic abstinence (e.g. calendar, 
ovulation, sy mptothermal, post -ovulation methods) and withdrawal are not acce ptable 
methods of contraception [Hatcher , 201 1].
1.Contraceptive subdermal implant
1.Intrauterine device or intrauterine s ystem
2.Combined estrogen and progestogen oral contraceptive 
3.Injectable progestogen
4.Contraceptive vaginal ring
5.Percutaneous contraceptive patches
6.Male partner sterilization with docume ntation of azoospermia prior to the female 
subject's entry  into the study , and this male is the sole partner for that subject. The 
documentation on male sterility  can come from the site personnel’s: review of 
subject’s medica l records, medical examination and/or semen anal ysis, or medical 
history  interview provided by  [CONTACT_163596].
7.Male condom plus partner use of one of the contraceptive options below that meets 
the standard operating procedure ( SOP)effectiveness criteria including a <1% rate of 
failure per year, as stated in the product label:
Contraceptive subdermal implant
Intrauterine device or intrauterine s ystem
Combined estrogen and progestogen or al contraceptive
Injectable progestogen
Contraceptive vaginal ring
Percutaneous contraceptive patches
These allowed methods of contraception are only  effective when used consistently , 
correctly  and in accordance with the product label. The investigator is responsible for 
ensuring that subjects understand how to properl y use these methods of contraception.
12.5.2. Collection of Pregnancy  Information
Investigator will collect pregnancy  information on any  female subject, who becomes 
pregnant while participating in this study
2016N302761_00 CONFIDENTIA L
[ADDRESS_938081]'s pregnancy .
Subject will be followed to determine the outcome of the pregnancy . The investigator 
will collect follow up information on mother and infant, which will be forwarded to [COMPANY_004].  
Generally , follow -up will not be required for longer than 6 to 8 weeks bey ond the 
estimated delivery  date. 
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.
While pregnancy  itself is not considered to be an AE or SAE, an y pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or SAE.
A spontaneous abortion is alway s considered to be an SAE and will be reported as such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered reasonabl y 
related to the stud y treatment by [CONTACT_093], will be reported to [COMPANY_004] as described in 
Section 9.1.[ADDRESS_938082] who becomes pregnant while participating will discontinue study  
medication or be withdrawn from the study .
12.5.3. Appendix 5References
Hatcher RA, Trus sell J, Nelson AL, Cates W Jr, Stewart F, Kowal D, Policar MS, 
editors. Contraceptive Technology . 20thedition. Atlanta, Georgia: Ardent Media, Inc., 
2011: 50. Table 3-2.
2016N302761_00 CONFIDENTIA L
[PHONE_14370].6. Appendix 6 -Division of AIDS Table For Grading The 
Severit y Of A dult And Paediatr icAverse Events Version 2.0, 
November 2014
PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
ESTIMATING SEVERITY GRADE
Clinical adverse 
event NOT identified 
elsewhere in the 
grading tableMild symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities with 
intervention not 
indicatedModerate 
symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention not 
indicatedSevere symptoms 
causi ng inability to 
perform usual social 
& functional activities 
with intervention or 
hospi[INVESTIGATOR_428125] -
threatening symptoms 
causing inability to 
perform basic self -care 
functions OR Medical or 
operative intervention 
indicated to preve nt 
permanent impairment, 
persistent disability, or 
death 
CARDIOVASCULAR
Arrhythmia
(by[CONTACT_691726])
Specify type, if
applicableNo symptoms 
AND No 
intervention 
indicatedNo symptoms AND
non-urgent 
intervention 
indicatedNon-life-threaten ing 
symptoms AND Non -
urgent intervention 
indicatedLife-threatening 
arrhythmia OR Urgent 
intervention indicated
Blood Pressure 
Abnormalities1 
Hypertension (with 
the lowest reading 
taken after repeat 
testing during a visit) 
≥ 18 years of age 140 to < 160 
mmHg systolic 
OR 90 to < 100 
mmHg diastolic ≥ 160 to < 180 
mmHg systolic OR 
≥ 100 to < 110 
mmHg diastolic ≥ 180 mmHg systolic 
OR ≥ 110 mmHg 
diastolic Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_373] 
< 18 years of age >120/80 mmHg ≥ 95th to < 99th 
percentile + 5 
mmHg adjusted for 
age, height, and 
gender (systolic 
and/or diastolic) ≥ 99th percentile + 5 
mmHg adjusted for 
age, height, and 
gender (s ystolic 
and/or diastolic) Life-threatening 
consequences in a 
participant not 
previously diagnosed 
with hypertension (e.g., 
malignant hypertension) 
OR Hospi[INVESTIGATOR_428126] (stable 
angina) OR New 
testing consistent 
with isch emia Unstable angina OR 
Acute myocardial 
infarction 
2016N302761_00 CONFIDENTIA L
[ADDRESS_938083] or 
with minimal activity 
or exertion (e.g., 
hypoxemia) OR 
Intervention indicated 
(e.g., oxygen) Life-threatening 
consequences OR 
Urgent intervention 
indicated (e.g., 
vasoactive medications, 
ventricular assist device, 
heart transplant) 
Hemorrhage (with 
significant acute 
blood loss) NA Symptoms AND No 
trans fusion 
indicated Symptoms AND 
Transfusion of ≤ 2 
units packed RBCs 
indicated Life-threatening 
hypotension OR 
Transfusion of >2 units 
packed RBCs (for 
children, packed RBCs 
> 10 cc/kg) indicated 
Prolonged PR 
Interval or AV Block 
Report only one 
> 16 y ears of age PR interval 0.21 
to < 0.25 seconds PR interval ≥ 0.25 
seconds OR Type I 
2nd degree AV 
block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
≤ [ADDRESS_938084] degree AV 
block (PR interval 
> normal for age 
and rate) Type I 2nd degree 
AV block Type II 2nd degree 
AV block OR 
Ventricular pause ≥ 
3.0 seconds Complete AV block 
Prolonged QTc 
Interval2 0.45 to 0.47 
seconds > 0.47 to 0.50 
seconds > 0.50 seconds OR ≥ 
0.06 seconds above 
baseline Life-threatening 
consequences (e.g., 
Torsade de pointes, 
other associated serious 
ventricular dysrhythmia) 
Thrombosis or 
Embolism 
Report only one NA Symptoms AND No 
intervention 
indicated Symptoms AND 
Intervention indicated Life-threatening embolic 
event (e.g., pulmonary 
embolism, thrombus) 
DERMATOLOGIC
Alopecia (scalp only) Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing gre ater 
than minimal 
interference with 
usual social & 
functional activities NA NA 
Bruising Localized to one 
area Localized to more 
than one area Generalized NA 
Cellulitis NA Non-parenteral 
treatment indicated 
(e.g., oral 
antibiotics, 
antifungals, 
antivirals) IV treatment 
indicated (e.g., IV 
antibiotics, 
antifungals, antivirals) Life-threatening 
consequences (e.g., 
sepsis, tissue necrosis) 
2016N302761_00 CONFIDENTIA L
205893
57PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperpi[INVESTIGATOR_428128] & 
functional 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Hypopi[INVESTIGATOR_428128] & 
functional 
activities Marked or 
generalized causing 
greater than 
minimal 
interference with 
usual social & 
functional activities NA NA 
Petechiae Localized to one 
area Localized to more 
than one area Generalized NA 
Pruritus3(without 
skin lesions) Itching causing no 
or minimal 
interference with 
usual social & 
functional 
activities Itching causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Itching causing 
inability to perform 
usual social & 
functional activities NA 
Rash 
Specify type, if 
applicable Localized rash Diffuse rash OR 
Target lesions Diffuse rash AND 
Vesicles or limited 
number of bullae or 
superficial ulcerations 
of mucous membrane 
limited to one site Extensive or generalized 
bullous lesions OR 
Ulceration of mucous 
membrane involving two 
or more distinct mucosal 
sites OR Stevens-
Johnson syndrome OR 
Toxic epi[INVESTIGATOR_691709]-threatening 
consequences (e.g., 
ketoacidosis, 
hyperosmolar non -
ketotic coma, end organ 
failure) 
Gynecomastia Detectable by 
[CONTACT_111186], 
caregiver, o r 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AND 
Causing pain with 
greater than 
minimal 
interference with 
usual social & 
functional activities Disfiguring changes 
AND Symptoms 
requiring intervention 
or causing inability to 
perform usual social 
& functional activities NA 
2016N302761_00 CONFIDENTIA L
205893
58PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Hyperthyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thy roid 
suppression 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_10821]-threatening 
consequences (e.g., 
thyroid storm) 
Hypothyroidism No symptoms 
AND Abnormal 
laboratory value Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Thyroid 
replacement 
therapy indicated Symptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despi[INVESTIGATOR_691710]-threatening 
consequences (e.g., 
myxedema coma) 
Lipoatrophy4 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functional 
activities Obvious on visual 
inspection AN D 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
Lipohypertrophy5 Detectable by 
[CONTACT_111186], 
caregiver, or 
physician AND 
Causing no or 
minimal 
interference with 
usual social & 
functiona l 
activities Obvious on visual 
inspection AND 
Causing greater 
than minimal 
interference with 
usual social & 
functional activities Disfiguring changes NA 
GASTROINTESTINAL
Anorexia Loss of appetite 
without decreased 
oral intake Loss of appetite 
associated with 
decreased oral 
intake without 
significant weight 
loss Loss of appetite 
associated with 
significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
Ascites No sy mptoms Symptoms AND 
Intervention 
indicated (e.g., 
diuretics, 
therapeutic 
paracentesis) Symptoms recur or 
persist despi[INVESTIGATOR_144482]-threatening 
consequences 
2016N302761_00 CONFIDENTIA L
205893
59PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Bloating or 
Distension 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cholecystitis NA Symptoms AND 
Medical intervention 
indicated Radiologic, 
endoscopic, or 
operative intervention 
indicated Life-threatening 
consequences (e.g., 
sepsis, perforation) 
Constipation NA Persistent 
constipation 
requiring regular 
use of dietary 
modifications, 
laxatives, or 
enemas Obstipation with 
manual evacuation 
indicated Life-threatening 
consequences (e.g., 
obstruction) 
Diarrhea ≥ 1 year of 
age Transient or 
intermittent 
epi[INVESTIGATOR_428130] ≤ 
3 stools over 
baseline per 24 -
hour period Persistent epi[INVESTIGATOR_428131] 4 to 6 
stools over baseline 
per 24- hour period Increase of ≥7 stools 
per 24- hour period 
OR IV fluid 
replacement 
indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Dysphagia or 
Odynophagia 
Report only one and 
specify location Symptoms but 
able to eat usual 
diet Symptoms causing 
altered dietary 
intake with no 
intervention 
indicated Symptoms causing 
severely altered 
dietary intake with 
intervention indicated Life-threatening 
reduction in oral intake 
Gastrointestinal 
Bleeding Not requiring 
intervention other 
than iron 
supplement Endoscopic 
intervention 
indicated Transfusion indicated Life-threatening 
consequences (e.g., 
hypotensive shock) 
Mucositis or 
Stomatitis 
Report only one and 
specify location Mucosal erythema Patchy 
pseudomembranes 
or ulcerations Confluent 
pseudomembranes 
or ulce rations OR 
Mucosal bleeding 
with minor trauma Life-threatening 
consequences (e.g., 
aspi[INVESTIGATOR_1516], choking) OR 
Tissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding 
Nausea Transient (< 24 
hours) or 
intermittent AND 
No or minimal 
interference with 
oral intake Persistent nausea 
resulting in 
decreased oral 
intake for 24 to 48 
hours Persistent nausea 
resulting in minimal 
oral intake for > 48 
hours OR 
Rehydration indicated 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
Pancreati tis NA Symptoms with 
hospi[INVESTIGATOR_184842]-threatening 
consequences (e.g., 
circulatory failure, 
hemorrhage, sepsis) 
2016N302761_00 CONFIDENTIA L
205893
60PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Perforation 
(colon or rectum) NA NA Intervention indicated Life-threatening 
consequences 
Proctitis Rectal discomfort 
with no 
intervention 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Medical 
intervention 
indicated Symptoms causing 
inability to perform 
usual social &
functional activities 
OR Operative 
intervention indicated Life-threatening 
consequences (e.g., 
perforation) 
Rectal Discharge Visible discharge Discharge requiring 
the use of pads NA NA 
Vomiting Transient or 
intermittent AND 
No or minimal 
interfe rence with 
oral intake Frequent epi[INVESTIGATOR_428132] 
(e.g., IV fluids) Life-threatening 
consequences (e.g., 
hypotensive shock) 
MUSCULOSKELETAL
Arthralgia Joint pain causing 
no or minimal 
interference with 
usual social & 
functional 
activities Joint pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Joint pain causing 
inability to perform 
usual social & 
functional activities Disabling joint pain 
causing inability to 
perform basic self -care 
functions 
Arthritis Stiffness or joint 
swelling causing 
no or minimal 
interference with 
usual social & 
functional 
activities Stiffness or joint 
swelling causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Stiffness or joint 
swelling causing 
inability to perform 
usual social & 
functional activities Disabling joint stiffness 
or swelling causing 
inability to perform basic 
self-care functions 
Myalgia 
(generalized) Muscle pain 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Muscle pain 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle pain causing 
inability to perfor m 
usual social & 
functional activities Disabling muscle pain 
causing inability to 
perform basic self -care 
functions 
Osteonecrosis NA No symptoms but 
with radiographic 
findings AND No 
operative 
intervention 
indicated Bone pain with 
radiographic findin gs 
OR Operative 
intervention indicated Disabling bone pain with 
radiographic findings 
causing inability to 
perform basic self -care 
functions 
Osteopenia6
≥ 30 years of age BMD t -score -2.5 
to -1 NA NA NA 
2016N302761_00 CONFIDENTIA L
205893
61PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
< 30 years of age BMD z -score -2 to 
-1 NA NA NA 
Osteoporosis6
≥ 30 years of age NA BMD t -score < -2.5 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
< 30 years of age NA BMD z -score < -2 Pathologic fracture 
(e.g., compression 
fracture causing loss 
of vertebral height) Pathologic fracture 
causing life -threatening 
consequences 
NEUROLOGIC
Acute CNS Ischemia NA NA Transient ischemic 
attack Cerebral vascular 
accident (e.g., stroke 
with neu rological deficit) 
Altered Mental 
Status (for 
Dementia, see 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance below) Changes causing 
no or minimal 
interference with 
usual social & 
functional 
activities Mild lethargy or 
somnolence 
causing greater 
than m inimal 
interference with 
usual social & 
functional activities Confusion, memory 
impairment, lethargy, 
or somnolence 
causing inability to 
perform usual social 
& functional activities Delirium OR 
Obtundation OR Coma 
Ataxia Symptoms 
causing no or 
minimal
interference with 
usual social & 
functional 
activities OR No 
symptoms with 
ataxia detected on 
examination Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Disabling symptoms 
causing inability to 
perform basic self -care 
functions 
Cognitive, 
Behavioral, or 
Attentional 
Disturbance 
(includes dementia 
and attention deficit 
disorder) 
Specify type, if 
applicable Disability causing 
no or mi nimal 
interference with 
usual social & 
functional 
activities OR 
Specialized 
resources not 
indicated Disability causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources on part -
time basis indicated Disab ility causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full-
time basis indicated Disability causing 
inability to perform basic 
self-care functions OR 
Institutionalization 
indicated 
Developmental Delay 
< 18 years of age 
Specify type, if 
applicable Mild 
developmental 
delay, either 
motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Moderate 
developmental 
delay, either motor 
or cognitive, as 
determi ned by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Severe 
developmental delay, 
either motor or 
cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either motor 
or cognitive, as 
determined by 
[CONTACT_7425] a 
developmental 
screening tool 
appropriate for the 
setting 
2016N302761_00 CONFIDENTIA L
205893
62PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Headache Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Symptoms causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428163] (includes 
myopathy and 
neuropathy) 
Specify type, if 
applicable Minimal muscle 
weakness causing 
no or minimal 
interference with 
usual social & 
functional 
activities OR No 
symptom s with 
decreased 
strength on 
examination Muscle weakness 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Muscle weakness 
causing inability to 
perform usual social 
& functional activities Disabling muscle 
weakness caus ing 
inability to perform basic 
self-care functions OR 
Respi[INVESTIGATOR_428134] (includes 
paresthesia and 
painful neuropathy) 
Specify type, if 
applicable Minimal 
paresthesia 
causing no or 
minimal 
interfer ence with 
usual social & 
functional 
activities OR No 
symptoms with 
sensory alteration 
on examination Sensory alteration 
or paresthesia 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Sensory alteration or 
paresthesia causing 
inability to perform 
usual social & 
functional activities Disabling sensory 
alteration or paresthesia 
causing inability to 
perform basic self -care 
functions 
Seizures New Onset 
Seizure 
≥ 18 years of age NA NA 1 to 3 seizures Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
< 18 years of age 
(includes new or pre -
existing febrile 
seizures) Seizure lasting < 
5 minutes w ith < 
24 hours postictal 
state Seizure lasting 5 to 
< 20 minutes with < 
24 hours postictal 
state Seizure lasting ≥ 20 
minutes OR > 24 
hours postictal state Prolonged and repetitive 
seizures (e.g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Pre-existing Seizure NA Increased 
frequency from 
previous level of 
control without 
change in seizure 
character Change in seizure 
character either in 
duration or quality 
(e.g., severity or 
focality) Prolonged and repetitive 
seizures (e .g., status 
epi[INVESTIGATOR_7397]) OR Difficult 
to control (e.g., 
refractory epi[INVESTIGATOR_002]) 
Syncope Near syncope 
without loss of 
consciousness 
(e.g., pre-
syncope) Loss of 
consciousness with 
no intervention 
indicated Loss of 
consciousness AND 
Hospi[INVESTIGATOR_691711] 
2016N302761_00 CONFIDENTIA L
205893
63PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
PREGNANCY, PUERPERIUM, AND PERINATAL
Fetal Death or 
Stillbirth (report 
using mother’s 
participant ID) 
Report only one NA NA Fetal loss occurring 
at ≥ 20 weeks 
gestation NA 
Preterm Delivery7
(report using 
mother’s participant 
ID) Delivery at 34 to < 
37 weeks 
gestational age Delivery at 28 to < 
34 weeks 
gestational age Delivery at 24 to < 28 
weeks gestational 
age Delivery at < 24 weeks 
gestational age 
Spontaneous 
Abortion or 
Miscarriage8(report 
using mother’s 
participant ID) 
Report only one Chemical 
pregnancy Uncomplicated 
spontaneous 
abortion or 
miscarriage Complicated 
spontaneous abortion 
or miscarriage NA 
PSYCHIATRIC
Insomnia Mild difficulty 
falling asleep, 
staying asleep, or 
waking up early Moderate difficult y 
falling asleep, 
staying asleep, or 
waking up early Severe difficulty 
falling asleep, staying 
asleep, or waking up 
early NA 
Psychiatric Disorders 
(includes anxiety, 
depression, mania, 
and 
psychosis) 
Specify disorder Symptoms with 
intervention not
indicated OR 
Behavior causing 
no or minimal 
interference with 
usual social & 
functional 
activities Symptoms with 
intervention 
indicated OR 
Behavior causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms with 
hospi[INVESTIGATOR_691712] & 
functional activities Threatens harm to self 
or others OR Acute 
psychosis OR Behavior 
causing inability to 
perform basic self -care 
functions 
Suicidal Ideation or 
Attempt 
Report only one Preoccupi[INVESTIGATOR_691713] 
2016N302761_00 CONFIDENTIA L
205893
64PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
RESPI[INVESTIGATOR_691714] 1 
second or peak 
flow reduced to ≥ 
70 to < 80% OR 
Mild symptoms 
with intervention 
not indicated Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 50 to < 
70% OR Symptoms 
with intervention 
indicated OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Forced expi[INVESTIGATOR_184849] 1 second 
or peak flow 25 to < 
50% OR Symptoms 
causing inability to 
perform usual so cial 
& functional activities Forced expi[INVESTIGATOR_184849] 1 second or 
peak flow < 25% OR 
Life-threatening 
respi[INVESTIGATOR_691715] & 
functional 
activities OR 
Wheezing OR 
Minimal increase 
in respi[INVESTIGATOR_428138] & 
functional activities 
OR Nasal flaring 
OR Intercostal 
retractions OR 
Pulse oximetry 90 
to < 95% Dyspnea at rest 
causing inability to 
perform usual social 
& functional activities 
OR Pulse oximetry < 
90% Respi[INVESTIGATOR_184852] (e.g., CPAP, 
BPAP, intubation) 
SENSORY
Hearing Loss 
≥ 12 years of age NA Hearing aid or 
intervention not 
indicated Hearing aid or 
intervention indicated Profound bilateral 
hearing loss (> 80 dB at 
2 kHz and above) OR 
Non-serviceable hearing 
(i.e., >50 dB audiogram 
and <50% speech 
discrimination) 
< 12 years of age 
(based on a 1, 2, 3, 
4, 6 and 8 kHz 
audiogram) > 20 dB hearing 
loss at ≤ 4 kHz > 20 dB hearing 
loss at > 4 kHz > 20 dB hearing loss 
at ≥ 3 kHz in one ear 
with additional 
speech language 
related services 
indicated (where 
available) OR 
Hearin g loss 
sufficient to indicate 
therapeutic 
intervention, including 
hearing aids Audiologic indication for 
cochlear implant and 
additional speech -
language related 
services indicated 
(where available) 
Tinnitus Symptoms 
causing no or 
minimal 
interference w ith 
usual social & 
functional 
activities with 
intervention not 
indicated Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities 
with intervention 
indicated Symptoms causing 
inability to perform 
usual social & 
functio nal activities NA 
2016N302761_00 CONFIDENTIA L
205893
65PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Uveitis No symptoms 
AND Detectable 
on examination Anterior uveitis with 
symptoms OR 
Medicamylasal 
intervention 
indicated Posterior or pan -
uveitis OR Operative 
intervention indicated Disabling visual loss in 
affected eye(s) 
Vertig o Vertigo causing 
no or minimal 
interference with 
usual social & 
functional 
activities Vertigo causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Vertigo causing 
inability to perform 
usual social & 
functional activities Disabling vertigo 
causing inability to 
perform basic self -care 
functions 
Visual Changes 
(assessed from 
baseline) Visual changes 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Visual changes 
causing greater 
than minimal 
interference with 
usual social & 
functional activities Visual changes 
causing inability to 
perform usual social 
& functional activities Disabling visual loss in 
affected eye(s) 
SYSTEMIC
Acute Allergic 
Reaction Localized urticaria 
(wheals) with no 
medic al 
intervention 
indicated Localized urticaria 
with intervention 
indicated OR Mild 
angioedema with 
no intervention 
indicated Generalized urticaria 
OR Angioedema with 
intervention indicated 
OR Symptoms of 
mild bronchospasm Acute anaphylaxis OR 
Life-threat ening 
bronchospasm OR 
Laryngeal edema 
Chills Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities NA 
Cytokine Release 
Syndrome9Mild signs and 
symptoms AND 
Therapy (i.e., 
antibody infusion) 
interruption not 
indicated Therapy (i.e., 
antibody infusion) 
interruption 
indicated AND 
Responds promptly 
to sy mptomatic 
treatment OR 
Prophylactic 
medications 
indicated for ≤ 24 
hours Prolonged severe 
signs and symptoms 
OR Recurrence of 
symptoms following 
initial improvement Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
Fatigue o r Malaise 
Report only one Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Symptoms causing 
inability to perform 
usual social & 
functional activities Incapacitating 
symptoms of fatigue or 
malaise causing inability 
to perform basic self -
care functions 
Fever (non-axillary 
temperatures only) 38.0 to < 38.6°C 
or 100.4 to < 
101.5°F ≥ 38.6 to < 39.3°C 
or ≥ 101.5 to < 
102.7°F ≥ 39.3 to < 40.0°C or 
≥ 102.7 to < 104.0°F ≥ 40.0°C or ≥ 104.0°F 
2016N302761_00 CONFIDENTIA L
205893
66PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Pain10(not 
associated with study 
agent injections and 
not specified 
elsewhere) 
Specify location Pain causing no 
or minimal 
interference with 
usual social & 
functional 
activities Pain causing 
greater than 
minimal 
interference with 
usual social & 
functional activities Pain causing inability 
to perform usual 
social & functional 
activities Disabling pain causing 
inability to perform basic 
self-care functions OR 
Hospi[INVESTIGATOR_428139]11 Mild signs and 
symptoms Moderate signs and 
symptoms AND 
Intervention 
indicated (e.g., 
antihistamines) Severe signs and 
symptoms AND 
Higher level 
intervention indicated 
(e.g., steroids or IV 
fluids) Life-threatening 
consequences (e.g., 
requiring pressor or 
ventilator support) 
Underweight12
> 5 to 19 years of 
age NA WHO BMI z -score < 
-2 to ≤ -3 WHO BMI z -score < -
3 WHO BMI z -score < -3 
with life -threatening 
consequences 
2 to 5 years of age NA WHO Weight -for-
height z -score 
< -2 to ≤ -3 WHO Weight -for-
height z -score < -3 WHO Weight -for-height 
z-score < -3 with life -
threatening 
consequences 
< 2 years of age NA WHO Weight -for-
length z -score 
< -2 to ≤ -3 WHO Weight -for-
length z -score < - 3 WHO Weight -for-length 
z-score < -3 with life -
threatening 
consequences 
Weight Loss 
(excludes postpartum 
weight loss) NA 5 to < 9% loss in 
body weight from 
baseline ≥ 9 to < 20%  loss in 
body weight from 
baseline ≥ 20% loss in body 
weight from baseline OR 
Aggressive intervention 
indicated (e.g., tube 
feeding, total parenteral 
nutrition) 
URINARY
Urinary Tract 
Obstruction NA Signs or symptoms 
of urinary tract 
obstruction without 
hydronephrosis or 
renal dysfunction Signs or symptoms of 
urina ry tract 
obstruction with 
hydronephrosis or 
renal dysfunction Obstruction causing life -
threatening 
consequences 
SITE REACTIONS TO INJECTIONS AND INFUSIONS
Injection Site Pain or 
Tenderness 
Report only one Pain or 
tenderness 
causing no or 
minimal limitation 
of use of limb Pain or tenderness 
causing greater 
than minimal 
limitation of use of 
limb Pain or tenderness 
causing inability to 
perform usual social 
& functional activities Pain or tenderness 
causing inability to 
perform basic self -care 
function OR 
Hospi[INVESTIGATOR_374] 
2016N302761_00 CONFIDENTIA L
205893
67PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Injection Site 
Erythema or 
Redness13 
Report only one 
> 15 years of age 2.5 to < 5 cm in 
diameter OR 6.25 
to < 25 cm2 
surface area AND 
Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activities ≥ 5 to < 10 cm in 
diameter OR ≥ 25 
to < 100 cm2 
surface area OR 
Symptoms causing 
greater than 
minimal 
interference with 
usual social & 
functional activities ≥ 10 cm in diameter 
OR ≥ 100 cm2 
surface area OR 
Ulceration OR 
Secondary infection 
OR Phlebitis OR
Sterile abscess OR 
Drainage OR 
Symptoms causing 
inability to perform 
usual social & 
functional activities Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
≤ 15 years of age ≤2.5 cm in 
diameter > 2.5 cm in 
diameter with < 
50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) ≥ 50% surface area 
of the extremity 
segment involved 
(e.g., upper arm or 
thigh) OR Ulceration 
OR Secondary 
infection OR Phlebitis 
OR Sterile abscess 
OR Drainage Potentially life -
threatening 
consequences (e.g., 
abscess, exfoliative 
dermatitis, necrosis 
involving dermis or 
deeper tissue) 
Injection Site 
Induration or 
Swelling 
Report only one 
> 15 years of age Same as for 
Injecti on Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, > 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, > 15 years of 
age 
≤ 15 years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 
years of age Same as for 
Injection Site 
Erythema or 
Redness, ≤ 15 years 
of age Same as for Injection 
Site Erythema or 
Redness, ≤ 15 years of 
age 
Injection Site Pruritus Itching localized 
to the injection 
site that is 
relieved 
spontaneously or 
in < 48 hours of 
treatment Itching beyond the 
injection site that is 
not generalized OR 
Itching localized to 
the injection s ite 
requiring ≥ 48 
hours treatment Generalized itching 
causing inability to 
perform usual social 
& functional activities NA 
LABORATORY VALUES Chemistries
Acidosis NA pH ≥ 7.3 to < LLN pH < 7.3 without life -
threatening 
consequences pH < 7.3 with li fe-
threatening 
consequences 
Albumin, Low (g/dL; 
g/L) 3.0 to < LLN 
30 to < LLN ≥ 2.0 to < 3.0
≥ 20 to < 30 < 2.0 
< 20 NA 
Alkaline 
Phosphatase, High 1.25 to < 2.[ADDRESS_938085] 2.5 to < 5.[ADDRESS_938086] 5.0 to < 10.[ADDRESS_938087] ≥ 10.[ADDRESS_938088] 
Alkalosis NA pH > ULN to ≤ 7.5 pH > 7.5 without life -
threatening 
consequences pH > 7.5 with life -
threatening 
consequences 
2016N302761_00 CONFIDENTIA L
205893
68PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
ALT or SGPT, High 
Report only one 1.25 to < 2.[ADDRESS_938089] 2.5 to < 5.[ADDRESS_938090] 5.0 to < 10.[ADDRESS_938091] ≥ 10.[ADDRESS_938092] 
Amylase (Pancreatic) 
or Amylase (Total), 
High 
Report only one 1.1 to < 1.[ADDRESS_938093] 1.5 to < 3.[ADDRESS_938094] 3.0 to < 5.[ADDRESS_938095] ≥ 5.[ADDRESS_938096] or SGOT, High 
Report only one 1.25 to < 2.[ADDRESS_938097] 2.5 to < 5.[ADDRESS_938098] 5.0 to < 10.[ADDRESS_938099] ≥ 10.[ADDRESS_938100] 
Bicarbonate, Low 
(mEq/L; mmol/L ) 16.0 t o < LLN 
16.0 to < LLN 11.0 to < 16.0 
11.0 to < 16.0 8.0 to < 11.0 
8.0 to < 11.0 < 8.0 
< 8.[ADDRESS_938101] 
Bilirubin14, High 
> 28 days of age NA NA > ULN > ULN with life -
threatening 
consequences (e.g., 
signs and symptoms of 
liver failure) 
≤ [ADDRESS_938102] to ≤ 1 mg/dL > 1 to ≤ 1.5 mg/dL > 1.5 to ≤ 2 mg/dL > 2 mg/dL 
Total Bilirubin, High 
> 28 days of age 1.1 to < 1.[ADDRESS_938103] 1.6 to < 2.[ADDRESS_938104] 2.6 to < 5.[ADDRESS_938105] ≥ 5.[ADDRESS_938106] 
≤ 28 days of age Total Bilirubin for 
Term and Preter m 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for 
Term and Preterm 
Neonates Total Bilirubin for Term 
and Preterm Neonates 
Calcium, High 
(mg/dL; mmol/L ) 
≥ 7 days of age 10.6 to < 11.5 
2.65 to < 2.88 11.5 to < 12.5 
2.88 to < 3.13 12.5 to < 13.5 
3.13 to < 3.38 ≥ 13.5 
≥ 3.38 
< 7 days of age 11.5 to < 12.4 
2.88 to < 3.10 12.4 to < 12.9 
3.10 to < 3.23 12.9 to < 13.5 
3.23 to < 3.38 ≥ 13.5 
≥ 3.38 
Calcium (Ionized), 
High (mg/dL; 
mmol/L ) > ULN to < 6.0
> ULN to < 1 .5 6.0 to < 6.4 
1.5 to < 1.6 6.4 to < 7.2 
1.6 to < 1.8 ≥ 7.2 
≥ 1.8 
Calcium, Low 
(mg/dL; mmol/L ) 
≥ 7 days of age 7.8 to < 8.4 
1.95 to < 2.10 7.0 to < 7.8 
1.75 to < 1.95 6.1 to < 7.0 
1.53 to < 1.75 < 6.1 
< 1.53 
< 7 days of age 6.5 to < 7. 5 
1.63 to < 1.88 6.0 to < 6.5 
1.50 to < 1.63 5.50 to < 6.0 
1.38 to < 1.50 < 5.50 
< 1.38 
Calcium (Ionized), 
Low (mg/dL; mmol/L ) < LLN to 4.0 
< LLN to 1.0 3.6 to < 4.0 
0.9 to < 1.0 3.2 to < 3.6 
0.8 to < 0.9 < 3.2 
< 0.8 
2016N302761_00 CONFIDENTIA L
205893
69PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Cardiac Troponin I, 
High NA NA NA Levels consistent with 
myocardial infarction or 
unstable angina as 
defined by [CONTACT_428225], 
High 3 to < [ADDRESS_938107] 6 to < [ADDRESS_938108] 10 to < [ADDRESS_938109] ≥ [ADDRESS_938110] > 1.[ADDRESS_938111] 
OR Increase of > 
0.3 mg/dL above 
baseline > 1.8 to < 3.[ADDRESS_938112] 
OR Increase of 1.5 to 
< 2.0 x above 
baseline ≥ 3.[ADDRESS_938113] OR 
Increase of ≥ 2.0 x 
above baseline 
Creatinine 
Clearance15or
eGFR, Low 
Report only one NA < 90 to 60 ml/min or 
ml/min/1.73 m2 OR 
10 to < 30% 
decrease from 
baseline < 60 to 30 ml/min or 
ml/min/1.73 m2 OR ≥ 
30 to < 50% 
decrease from 
baseline < 30 ml/min or 
ml/min/1.73 m2 OR ≥ 
50% decrease from 
baseline or dialys is 
needed 
Glucose 
(mg/dL; mmol/L ) 
Fasting, High 110 to 125 
6.11 to < 6.95 > 125 to 250 
6.95 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Nonfasting, High 116 to 160 
6.44 to < 8.89 > 160 to 250 
8.89 to < 13.89 > 250 to 500 
13.89 to < 27.75 > 500 
≥ 27.75 
Glucose, Low 
(mg/dL; mmol/L ) 
≥ 1 month of age 55 to 64 
3.05 to 3.55 40 to < 55 
2.22 to < 3.05 30 to < 40 
1.67 to < 2.22 < 30 
< 1.[ADDRESS_938114] to < 2.[ADDRESS_938115] without 
acidosis ≥ 2.[ADDRESS_938116] without 
acidosis Increased lactate with 
pH < 7.3 without life -
threatening 
consequences Increased lactate with 
pH < 7.3 with life -
threatening 
consequences 
Lipase, High 1.1 to < 1.[ADDRESS_938117] 1.5 to < 3.[ADDRESS_938118] 3.0 to < 5.[ADDRESS_938119] ≥ 5.[ADDRESS_938120] 
Lipid Disorders 
(mg/dL; mmo l/L) 
Cholesterol, Fasting, 
High 
≥ 18 years of age 200 to < 240 
5.18 to < 6.19 240 to < 300 
6.19 to < 7.77 ≥ 300 
≥ 7.77 NA 
< 18 years of age 170 to < 200 4.40 
to < 5.15 200 to < 300 5.15 to 
< 7.77 ≥ 300 ≥ 7.77 NA 
LDL, Fasting, High 
≥ 18 ye ars of age 130 to < 160 3.37 
to < 4.12 160 to < 190 4.12 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
2016N302761_00 CONFIDENTIA L
205893
70PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
> 2 to < 18 years of 
age 110 to < 130 2.85 
to < 3.34 130 to < 190 3.34 to 
< 4.90 ≥ 190 ≥ 4.90 NA 
Triglycerides, 
Fasting, High 150 to 300 
1.71 to 3.42 >300 to 500 
>3.42 to 5.7 >500 to < 1,000 
>5.7 to 11.4 > 1,000 
> 11.4 
Magnesium16, Low 
(mEq/L; mmol/L ) 1.2 to < 1.4 
0.60 to < 0.70 0.9 to < 1.2 
0.45 to < 0.60 0.6 to < 0.9 
0.30 to < 0.45 < 0.6 
< 0.30 
Phosphate, Low 
(mg/dL; mmol/L ) 
> 14 years of ag e 2.0 to < LLN 
0.81 to < LLN 1.4 to < 2.0 
0.65 to < 0.81 1.0 to < 1.4 
0.32 to < 0.65 < 1.0 
< 0.32 
1 to 14 years of age 3.0 to < 3.5 
0.97 to < 1.13 2.5 to < 3.0 
0.81 to < 0.97 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
< 1 year of age 3.5to < 4.5 
1.13 to < 1.45 2.5 to < 3.5 
0.81 to < 1.13 1.5 to < 2.5 
0.48 to < 0.81 < 1.5 
< 0.48 
Potassium, High 
(mEq/L; mmol/L ) 5.6 to < 6.0 
5.6 to < 6.0 6.0 to < 6.5 
6.0 to < 6.5 6.5 to < 7.0 
6.5 to < 7.0 ≥ 7.0 
≥ 7.0 
Potassium, Low 
(mEq/L ; mmol/L ) 3.0 to < 3.4 
3.0 to < 3.4 2.5 to < 3.0 
2.5 to < 3.0 2.0 to < 2.5 
2.0 to < 2.5 < 2.0 
< 2.0 
Sodium, High 
(mEq/L; mmol/L ) 146 to < 150 
146 to < 150 150 to < 154 
150 to < 154 154 to < 160 
154 to < 160 ≥ 160 
≥ 160 
Sodium, Low 
(mEq/L; mmol/L ) 130 to < 135 
130 to < 135 125 to < 130 
125 to < 135 121 to < 125 
121 to < 125 ≤ 120 
≤ 120 
Uric Acid, High 
(mg/dL; mmol/L ) 7.5 to < 10.0 
0.45 to < 0.59 10.0 to < 12.0 
0.59 to < 0.71 12.0 to < 15.0 
0.71 to < 0.89 ≥ 15.0 
≥ 0.89 
HEMATOLOGY
Absolute CD4+ 
Count, Low 
(cell/mm3; cells/L ) 
> 5 years of age (not 
HIV infected) 300 to < 400 
300 to < 400 200 to < 300 
200 to < 300 100 to < 200 
100 to < 200 < 100 
< 100 
Absolute Lymphocyte 
Count, Low 
(cell/mm3; cells/L ) 
> 5 years of age 
(not HIV infected) 600 to < 650 
0.600 x 109to < 
0.650 x 109500 to < 600 
0.500 x 109to < 
0.600 x 109350 to < 500 
0.350 x 109to < 
0.500 x 109< 350 
< 0.350 x 109
2016N302761_00 CONFIDENTIA L
205893
71PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
Absolute Neutrophil 
Count (ANC), Low 
(cells/mm3; cells/L ) 
> 7 days of a ge 800 to 1,000 
0.800 x 109to 
1.000 x 109600 to 799 
0.600 x 109to 0.799 
x 109400 to 599 
0.400 x 109to 0.599 
x 109< 400 
< 0.400 x 109
2 to 7 days of age 1,250 to 1,500 
1.250 x 109to 
1.500 x 1091,000 to 1,249 
1.000 x 109to 1.249 
x 109750 to 999 
0.750 x 109to 0.999 
x 109< 750 
< 0.750 x 109
≤ 1 day of age 4,000 to 5,000 
4.000 x 109to 
5.000 x 109 3,000 to 3,999 
3.000 x 109to 3.999 
x 1091,500 to 2,999 
1.500 x 109to 2.999 
x 109< 1,500 
< 1.500 x 109
Fibrinogen, 
Decreased (mg/dL; 
g/L) 100 to < 200 
1.00 to < 2.00 OR 
0.75 to < 1.[ADDRESS_938121] 75 to < 100 
0.75 to < 1.00 OR ≥ 
0.50 to < 0.[ADDRESS_938122] 50 to < 75 
0.50 to < 0.75 OR 
0.25 to < 0.[ADDRESS_938123] < 50 
< 0.50 OR < 0.[ADDRESS_938124] 
OR Associated with 
gross bleeding 
Hemoglobin17, Low 
(g/dL; mmol/L )18 
≥ 13 years of age 
(male only) 10.0 to 10 .9 
6.19 to 6.76 9.0 to < 10.0 
5.57 to < 6.19 7.0 to < 9.0 
4.34 to < 5.57 < 7.0 
< 4.34 
≥ 13 years of age 
(female only) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
57 days of age to < 
13 ye ars of age 
(male and female) 9.5 to 10.4 
5.88 to 6.48 8.5 to < 9.5 
5.25 to < 5.88 6.5 to < 8.5 
4.03 to < 5.25 < 6.5 
< 4.03 
36 to 56 days of age 
(male and female) 8.5 to 9.6 
5.26 to 5.99 7.0 to < 8.5 
4.32 to < 5.26 6.0 to < 7.0 
3.72 to < 4.3 2 < 6.0 
< 3.72 
22 to 35 days of age 
(male and female) 9.5 to 11.0 
5.88 to 6.86 8.0 to < 9.5 
4.94 to < 5.88 6.7 to < 8.0 
4.15 to < 4.94 < 6.7 
< 4.15 
8 to ≤ 21 days of age 
(male and female) 11.0 to 13.0 
6.81 to 8.10 9.0 to < 11.0 
5.57 to < 6.81 8.0 to < 9.0 
4.96 to < 5.57 < 8.0 
< 4.96 
≤ 7 days of age 
(male and female) 13.0 to 14.0 
8.05 to 8.72 10.0 to < 13.0 
6.19 to < 8.05 9.0 to < 10.0 
5.59 to < 6.19 < 9.0 
< 5.59 
INR, High 
(not on 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_938125] 1.5 to < 2.[ADDRESS_938126] 2.0 to < 3.[ADDRESS_938127] ≥ 3.[ADDRESS_938128] 
Methemoglobin (% 
hemoglobin) 5.0 to < 10.0% 10.0 to < 15.0% 15.0 to < 20.0% ≥ 20.0% 
2016N302761_00 CONFIDENTIA L
205893
72PARAMETER GRADE 1
MILDGRADE 2
MODERATEGRADE 3
SEVEREGRADE 4
POTENTIALLY
LIFE -THREATENING
PTT, High 
(noton 
anticoagulation 
therapy) 1.1 to < 1.[ADDRESS_938129] 1.66 to < 2.[ADDRESS_938130] 2.33 to < 3.[ADDRESS_938131] ≥ 3.[ADDRESS_938132] 
Platelets, Decreased 
(cells/mm3; cells/L ) 100,000 to < 
124,999 100.000 
x 109to < 124.999 
x [ZIP_CODE],000 to < 100,000 
50.000 x 109to < 
100.000 x 109 25,000 to < 50,000 
25.000 x 109to < 
50.000 x 109< 25,000 < 25.000 x 109
PT, High 
(not on 
anticoagulation 
therapy 1.1 to < 1.[ADDRESS_938133] 1.25 to < 1.[ADDRESS_938134] 1.50 to < 3.[ADDRESS_938135] ≥ 3.[ADDRESS_938136] 
WBC, Decreased 
(cells/mm3; cells/L ) 
> 7 days of a ge 2,000 to 2,499 
2.000 x 109to 
2.499 x 1091,500 to 1,999 
1.500 x 109to 1.999 
x 1091,000 to 1,499 
1.000 x 109 to 1.499 
x 109< 1,000 
< 1.000 x 109
≤ 7 days of age 5,500 to 6,999 
5.500 x 109to 
6.999 x 109 4,000 to 5,499 
4.000 x 109to 5.4 99 
x 1092,500 to 3,999 
2.500 x 109to 3.999 
x 109< 2,500 
< 2.500 x 109
URINALYSIS
Glycosuria ( random 
collection tested by 
[CONTACT_5230]) Trace to 1+ or 
≤ 250 mg 2+ or ˃  250to 
≤ 500 mg > 2+ or > 500 mg NA 
Hematuria (not to be 
reported based on
dipstick findings or 
on blood believed to 
be of menstrual 
origin) 6 to < 10 RBCs 
per high power 
field ≥ 10 RBCs per high 
power field Gross, with or without 
clots OR With RBC 
casts OR Intervention 
indicated Life-threatening 
consequences 
Proteinuria (random 
collection tested by 
[CONTACT_5230]) 1+ 2+ 3+ or higher NA 
1. Blood pressure norms for children < 18 years of age can be found in: Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduct ion in Children and Adolescents [Pediatrics, 2011 ];128;S213; originally 
published online November 14, 2011; DOI: 10.1542/peds.2009 -2107C. 
2. As per Bazett’s formula.  
3. For pruritus associated with injections or infusions, see the Site Reactions to Injections and Infusions section 
(page 23 ).  
4. Definition: A disorder characterized by [CONTACT_184941], extremities, and buttocks. 
5. Definition: A disorder characterized by [CONTACT_184942], breasts, and abdomen.  
6. BMD t and z scores can be fou nd in : [Kanis, 2007]JA on behalf of the World Health Organization Scientific Group 
(2007). Assessment of osteoporosis at the primary health -care level. Technical Report. World Health Organization 
2016N302761_00 CONFIDENTIA L
205893
73Collaborating Centre for Metabolic Bo ne Diseases, University of Sheffield, [LOCATION_006]. 2007: Printed by [CONTACT_308286].
7. Definition: A delivery of a live -born neonate occurring at ≥ 20 to < 37 weeks gestational age. 
8. Definition: A clinically recognized pregnancy occurring at < 20 weeks ge stational age.  
9. Definition: A disorder characterized by [CONTACT_33234], headache, tachycardia, hypotension, rash, and/or shortness of 
breath. 
10. For pain associated with injections or infusions, see the Site Reactions to Injections and Infusions section ( page 
23).
11. Definition: A disorder characterized by [CONTACT_411], arthralgia, myalgia, skin eruptions, lymphadenopathy, marked 
discomfort, and/or dyspnea.
12. WHO reference tables may be accesed by [CONTACT_184944]: 
http://www.who .int/growthref/who2007_bmi_for_age/en/ for participants > 5 to 19 years of age and 
http://www.who.int/childgrowth/standards/chart_catalogue/en/ for those ≤ [ADDRESS_938137] bilirubin > 1.5 mg/dL in a participant < 28 days of age should be graded as grade 2, if < 10% of the total 
bilirubin.  
15. Use the applicable formula (i.e., Cockroft -Gault in mL/min or Schwatrz in mL/min/1. 73m2).  
16. To convert a magnesium value from mg/dL to mmol/L, laboratories should multiply by 0.4114.  
17. Male and female sex are defined as sex at birth. 
18. The conversion factor used to convert g/dL to mmol/L is 0.[ADDRESS_938138] be converted to g/dL using the appropriate conversion factor for the particular laboratory.  
Appendix 6 References
Kanis JAon behalf of the World Health Organization Scientific Group (2007) 
Assessment of osteoporosis at the primary  health -care level. Technical Report. World 
Health Organization Collaborating Centre for Metabolic Bone Diseases, University  of 
Sheffield, [LOCATION_006]. 2007 : Printed by  [CONTACT_385864] y of Sheffield.
Expert Panel on I ntegrated Guidelines for Cardiovascular Health and Risk Reduction in 
Children and Adolescents: Summary  Report. Pediatrics  Dec 2011,  128  (Supplement 5)  
S213 -S256;  DOI : 10.1542/peds.2009-2107C.
2016N302761_00 CONFIDENTIA L
[PHONE_14371].7. Appendix 7:  Toxicity  Management
12.7.1. ANEMIA
Grade 1 (mild) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_938139] be repeated with the 
following additional tests:
1. peripheral blood smear
2. indirect bilirubin (abnormal if increased > 50% from baseline)
3. haptoglobin (abnormal if 25 mg/dL)
4. reticulocy te count (abnormal if  4%)
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of he moly tic 
anemia as specified above, subjects will permanently  discontinue study  medication and 
be withdrawn from the trial.  Subjects should be followed up until resolution of anemia.
Grade 2 (moderate) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_938140] be repeated with the 
following additional tests:
1.peripheral blood smear
2. indirect bilirubin (abnormal if increased >50% from baseline)
3.haptoglobin (abnormal if  25 mg/dL)
4.reticulocy te count (abnormal if  4%)
If the additional tests are within the normal range, subjects may  continue study  
medication.  If one or more of the additional tests is abnormal or suggestive of hemoly tic 
anemia as specified above, subjects will permanently  discontinue study  medication and 
be withdrawn from the trial.  Consultation with a Hematologist should be considered.  
Subjects should be followed up until resolution of anemia.
Grade 3 (severe) or Grade 4 (potentially life threatening) hemoglobin decrease:
Any hemoglobin decrease meeting the definition of Grade [ADDRESS_938141] be repeated with 
the following additional tests:
1.peripheral blood smear
2. indirect bilirubin
3.haptoglobin
4.reticulocy te count
Subjects will permanently discontinue stud y medication and be withdrawn from the trial.  
Consultation with a Hema tologist should be considered.  Subjects should be followed up 
until resolution of anemia.
2016N302761_00 CONFIDENTIA L
[PHONE_14372].7.2. TOTA L BILIRUBIN ELEVA TION
Grade 1 (mild) bilirubin elevation (1.[ADDRESS_938142]) or Grade 2 (moderate 
-1.6-2.[ADDRESS_938143]):
Any bilirubin value above the upper lim it of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects may  continue study  medication.  Subjects should 
be followed up until resolution (return to baseline) of elevation.
Grade 3 (severe –2.6-5.[ADDRESS_938144]) or 4 (life- threatening - >5.[ADDRESS_938145]) 
bilirubin elevation:
Any bilirubin value above the upper limit of normal must be repeated and fractionated 
(direct and indirect bilirubin).  Subjects will permanently  discontinue study medication 
and be withdrawn from the trial. Subjects should be followed up until resolution (return 
to baseline) of bilirubin elevation.
12.7.3. AST AND ALT ELEVA TION
See Section 12.2.
12.7.4. RASH
Grade 1 rash (Localized macular rash):
Subjects with Grade [ADDRESS_938146].  The stud y drug should be permanently  discontinued if the following signs 
or sy mptoms are noted at any  time:
1.Temperature >38. 5°C
2.Lym phadenopathy
3.Phary ngitis
4.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_938147] should remain on the study  to be 
followed for safety and PK as outlined in Section 9.1and Section 9.3.
2016N302761_00 CONFIDENTIA L
205893
76Grade 2 rash (Diffuse macular, maculopapular, or morbilliform rash OR Target 
lesions):
Subjects with Grade [ADDRESS_938148].  The study  drug should be permanentl y 
discontinued if the following signs or s ymptoms are noted at an y time:
1.Temperature >38.5°C
2.Lym phadenopathy
3.Phary ngitis
4.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_938149] should remain on the study to be followed for safety and PK as 
outlined in Section 9.1and Section 9.3.
Grade 3 rash (Diffuse macular, maculopapular, or morbilliform rash with vesicles 
or limited number of bullae OR Superficial ulcerations of mucous membrane 
limited to one site):
Subjects with a Grade [ADDRESS_938150] should be evaluated in the physician’s office immediatel y and should be seen in 
the phy sician’s office or contact[CONTACT_428226]  [ADDRESS_938151] should remain on the 
study  to be followed for safet y and PK as outlined in Section 9.1and Section 9.3.
Grade 4 rash (Extensive or generalized bullous lesions OR Stevens -Johnson 
syndrome OR Ulceration of mucous membrane involving two or more distinct 
mucosal sites OR Toxic epi[INVESTIGATOR_194] (TEN)):
Subjects wi th a Grade [ADDRESS_938152] should remain on the stud y to be followed 
for safety  and PK as outlined Section 9.1 and Section 9.3.
12.7.5. ALLERGIC RE ACTION
Grade 1 allergic reaction (Pruitis without rash):
Subjects with Grade 1 allergic reaction should be evaluated b y the Investigator 
immediately .  The stud y drug should be permanently  discontinued if the following signs 
or symptoms are noted at any  time:
1.Temperature >38.5°C
2.Eosinophilia
3.Respi[INVESTIGATOR_428141], lary ngospasm, or angioedema
4.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_938153] the Investigator immediatel y if there is an y worsening of the allergic 
reaction and/or if an y systemic si gns or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard 
management, including discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may  
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_691716].  The subject should remain on the study  to be 
followed for saf ety and PK as outlined Section 9.1and Section 9.3.
Grade 2 allergic reaction (Localized urticaria):
Subjects with Grade 2 allergic reaction should be evaluated b y the Investigator 
immediately .  The study  drug willbe permanently discontinued if the following signs or 
symptoms are noted at any  time:
1.Temperature > 38.5°C
2.Eosinophilia
3.Respi[INVESTIGATOR_428141], lary ngospasm, or angioedema
4.Any indication of internal organ involvement (hepatitis, nephritis)
In the absence of the above signs or s ymptoms, subjects with Grade [ADDRESS_938154] the Investigator immediatel y if the re is an y worsening of the allergic 
reaction and/or if an y systemic signs or s ymptoms worsen.  If the allergic reaction is 
considered to be most likely  due to concomitant illness or non -study  medication, standard 
management, including discontinuation of the likely  causative agent, should be 
undertaken.  If no other causative factor is found after clinical evaluation, the subject may 
be treated s ymptomatically  until the rash resolves. Antihistamines, topi[INVESTIGATOR_691717].  The subject should remain on the study  to be 
followed for safet y and PK as outlined in Section 9.1and Section 9.3.
2016N302761_00 CONFIDENTIA L
205893
78Grade 3 allergic reaction (Generalized urticaria or angioedema):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Grade 4 allergic reaction (Anaphylaxis):
Subjects will permanently discontinue the stud y medication and be withdrawn from the 
trial.  Subjects will be treated as clinically appropriate.  Subjects should be followed up 
until resolution of the adverse event and standard management should be undertaken.
Revised ACTG Toxicity Grade Definitions Investigator Action
Grade 1 Pruritus without rash May continue therapy
Grade 2 Localized urticaria May continue therapy
Grade 3 Generalized urticaria, Angioedema Disconti nue Therapy
Grade 4 Anaphylaxis Discontinue Therapy
12.7.6. CREA TINE PHOSPHA TE (CPK) ELEVA TION
Grade 3 or higher:
A Grade 3 or higher elevation in CPK should result in a repeat assessment within 2 to 4 
weeks to ensure the result is transient or due to exercise and will not require a change in 
study  treatment. A history  regarding use of drugs known to cause increase of CPK (such 
as statins) phy sical activity  or exercise preceding the CPK evaluation should be obtained.
Grade [ADDRESS_938155] has 
abstained from exercise for >[ADDRESS_938156] withdrawn from the study .
2016N302761_00 CONFIDENTIA L
[PHONE_14373].8. Appendix 8: Palatability  Questionnaire
The following questionnaire will be administered to each subject within [ADDRESS_938157] # : _________________________   Date: __________   Treatment:______
Page [ADDRESS_938158] in your own words (one word, short 
phrase descriptions are acceptable).
2.Please rate the palatability (accept ability  of taste) of the product by  [CONTACT_62262] a rating 
below.
____1 = unacceptable (would not use product under an y circumstances) 
____2 = neutral/acceptable
____3 = very  good
3.Please check allthe descriptors that apply to the product.
______ Sweet
______ Sour/tart
______ Bitter
______ Fruit y
______ Nutty
______ Chalky
______ Medicinal
4.Please select the descriptor y ou most closel y associate with the flavor of the product 
(i.e., select one).
______ Sweet
______ Sour/tart
______ Bitter
______ Fruit y
______ Nutty
______ Chalky
______ Medicinal
______ Other (please specify )_____________________
2016N302761_00 CONFIDENTIA L
[ADDRESS_938159] # : _________________________   Date: __________   Treatment:______
Page [ADDRESS_938160] b y checking a rating below.
_____ 1= unac ceptable (would not use product under any  circumstances)
_____ 2= neutral/acceptable
_____ 3= very  good
6.Please rate the aroma of the product b y checking a rating below.
____1 = unpleasant/unacceptable aroma
____2 = neutral/acceptable aroma
____3 = pleasant /desirable aroma
7.Please rate the product aftertaste b y checking a rating below.
____1 = unpleasant/unacceptable (e.g. need/desire to wash taste out of mouth)
____2 = neutral/acceptable
____3 = pleasant/desirable
2016N302761_00 CONFIDENTIA L
[ADDRESS_938161] # : _________________________   Date: __________   Treatment:______
Page [ADDRESS_938162] describes y our 
perception of each attribute. 
g.Flavor intensit yMild Average Strong
1 2 3 4 5
h.Aroma Mild Average Strong
1 2 3 4 5
i.Sweetness Not Sweet Sweet Very  Sweet
1 2 3 4 5
j.Sour/tartness Mild Average Strong
[ADDRESS_938163] # : _________________________   Date: __________   Treatment:______
Page 4 of 4
9.Based on your response to #8, please circle the number on a scale of [ADDRESS_938164] where:
1 = Reduce as much as possible
3 = Leave as is
5 = Increase as much as possible
l.Flavor intensit y Reduce Leave as is Increase
1 2 3 4 5
m.Aroma
1 2 3 4 5
n.Sweetness
1 2 3 4 5
o.Sour/tartness
[ADDRESS_938165] on a scale of 1 to 3, where:
____1 = unpleasant
____2 = neutral/acceptable
____3 = pl easant/desirable
11.Do y ou have an y other suggestions for changing/improving the flavor of this 
product?